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PREFACE AND DECLARATION 
 
For centuries, plants have been utilised for dietary supplementation and medicinal properties. 
These medicinal plants play a pivotal role in the traditional treatment of a variety of diseases. 
One such plant is Moringa oleifera (MO), an indigenous tree to India, found throughout South 
Africa (SA). Almost all parts of the tree are used either for dietary supplementation or medicinal 
properties. However the nutritious leaves possess a wide range of bioactive compounds that 
display anticancer, anti-inflammatory and antimicrobial activity among several others. In SA, 
majority of the population are relatively poor and rely on traditional medicines of which MO 
forms part of their remedy. Lung and oesophageal cancers are the leading causes of death in SA. 
Current cancer therapies are expensive with many side-effects therefore cheap, alternate 
traditional plant therapies are being actively investigated. Nanoparticles are also showing 
potential as a cancer therapeutics and can be easily synthesised using plant extracts such as MO 
leaf extract (MOE). This green chemistry can be advantageous especially in large scale 
production. Gold nanoparticles (AuNP’s) was successfully synthesised from MOE (MLAuNP). 
This study established the use of MOE as a complementary and alternate medicine in the 
treatment of both lung and oesophageal cancers. In addition, MLAuNP also showed potential in 
the treatment of lung cancer. Their mode of action was to induce cancer cell apoptosis with 
minimal effect on normal healthy cells. It can be concluded that SA’s traditional tree can be 
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Cancer is one of the leading causes of global mortality. In South Africa (SA), the burden of 
cancer (lung and oesophageal) continues to increase. Moringa oleifera (MO), indigenous to 
India, is found widely in SA and used in traditional treatments of cancer. Gold nanoparticles 
(AuNP’s) are showing potential in cancer therapies and can be synthesised using plants extracts 
such as MO leaf extract (MOE). This study investigated the antiproliferative effect of MOE and 
AuNP’s synthesised from MOE (MLAuNP) in A549 lung and SNO oesophageal cancer cells.  
 
MO crude aqueous leaf extract was prepared and cytotoxicity (MTT assay) was assessed in 
A549, SNO cells and normal peripheral blood mononuclear cells (PBMCs) (24h). Oxidative 
stress, DNA fragmentation and apoptotic markers were determined. A one-pot green synthesis 
technique using MOE to synthesise MLAuNP was then conducted. A549, SNO cells and PBMCs 
were also exposed to MLAuNP and CAuNP to evaluate cytotoxicity and apoptotic markers. 
 
MOE was cytotoxic to A549 cells. MOE (IC50: 166.7μg/ml, 24h) significantly increased lipid 
peroxidation, decreased glutathione (GSH) and Nrf2 levels leading to DNA fragmentation. 
MOE induced apoptosis by significantly increasing p53, caspase-9, enhancing caspase-3/7 
activities and Smac/DIABLO expression. MOE significantly cleaved PARP-1 into 89kDa and 
24kDa fragments. 
 
MOE was not cytotoxic to PBMCs but in SNO cells (IC50: 389.2µg/ml, 24h), it significantly 
increased lipid peroxidation, DNA fragmentation, decreased GSH, catalase and Nrf2 levels. 
Apoptosis was confirmed by the significant increase in phosphatidylserine (PS) externalisation, 
caspase-9, enhanced caspase-3/7 activities and significant decrease in ATP levels. MOE 
significantly increased p53, Smac/DIABLO and cleavage of PARP-1, resulting in an increase in 
the 24kDa fragment.   
 
MLAuNP was successfully synthesised. MLAuNP and CAuNP were not cytotoxic to PBMCs, whilst its 
pro-apoptotic properties were confirmed in A549 (IC50: MLAuNP - 98.46µg/ml; CAuNP  - 
121.4µg/ml) and SNO (IC50: MLAuNP - 92.01µg/ml; CAuNP  - 410.4µg/ml) cells. MLAuNP 
significantly increased caspase activity in SNO cells while MLAuNP significantly increased PS 
externalisation, mitochondrial depolarisation, caspase-9, caspase-3/7 activities and decreased 
ATP levels. Also, MLAuNP significantly increased p53, Bax, Smac/DIABLO, PARP-1 24kDa 





Hsp70, Skp2, Fbw7α, c-myc levels and activated alternate splicing with caspase-9a splice 
variant being increased. 
 
These findings indicate that MOE exerts antiproliferative effects in cancerous A549 and SNO 
cells by increasing oxidative stress, DNA fragmentation and inducing apoptosis. MLAuNP also 
possessed antiproliferative properties in SNO cells and induced apoptosis in A549 cells by 
modulating oncogenes, tumour suppressor genes and activating alternate splicing of caspase-9. 
MOE and MLAuNP showed potential use as a complementary and alternative treatment for lung 
and oesophageal cancer. MOE fractionation studies are further recommended to identify the 
bioactive compounds responsible for the antiproliferative effect seen in A549 and SNO cells. In 
addition, membrane transport proteins as well as cell cycle analysis will provide further insight 


























Cancer is amongst the major noncommunicable diseases causing death worldwide [1, 2]. Cancer 
alone accounts for 21.7% of all noncommunicable diseases. In 2012, approximately 8.2 million 
deaths occurred due to cancer. The annual cancer mortality is expected to increase to 12.6 
million by year 2030. The burden of cancer is increasing in both developed and developing 
countries as a result of increased tobacco use, alcohol consumption, physical inactivity, diet and 
lifestyle [3]. In addition, inhalation of air-borne pollutants, occupational exposure to chemicals 
and toxins, family history and burden of infectious diseases are also factors associated with 
cancer pathogenesis [4, 5].  
 
In South Africa (SA) the healthcare burden is compounded by the presence of infectious 
diseases such as Human immunodeficiency virus (HIV)/Acquired immune deficiency syndrome 
(AIDS), Mycobacterium tuberculosis (MtB) infections in addition to cancer and other 
noncommunicable diseases [6]. HIV causes immune dysfunction, disease progression and 
susceptibility to secondary infections e.g. tuberculosis (TB) [7] with multi drug-resistant (MDR) 
and extremely drug-resistant (XDR) TB accounting for 10% of all TB cases. The majority of 
South Africans are at a higher risk of developing cancers (especially lung and oesophageal) due 
to lifestyle changes and high burden of these infectious diseases [8]. In SA, lung and 
oesophageal cancers commonly have high mortality rates which are a major concern.   
 
Cellular homeostasis is maintained via cell proliferation and apoptosis (programmed cell death) 
[9]. Cancer cells evade apoptosis and proliferate through activation of oncogenes e.g. c-myc, 
and inactivation of tumour suppressor genes e.g. p53. Apoptosis occurs via two pathways 
namely the death receptor - mediated procaspase - activation (extrinsic) pathway or 
mitochondrion - mediated procaspase - activation (intrinsic) pathway [10, 11]. The pathways are 
activated via apoptotic stimuli i.e. reactive oxygen species (ROS), decreased antioxidant 
response and DNA damage [9]. In addition, the aspartate-specific cysteine proteases (caspases) 
cause the cleavage of proteins and execution of the apoptotic cascade. 
 
Overexpression of c-myc is seen in many cancers which result in cancer cell proliferation and 
evasion of apoptosis [12]. It is post-translationally regulated by S-phase kinase-associated 
protein 2 (Skp2) and F-box and WD repeat domain-containing 7 α (Fbw7α) which forms 
subunits of SCF-type E3 ligase responsible for proteasomal degradation. Skp2 and Fbw7α can 





be effective for cancer therapeutics. In addition, regulation of genes and proteins determines 
cellular fate which can also aid in the development of chemotherapeutic agents. This is evident 
by the alternate splicing mechanism which determines which variant of a gene is translated 
resulting in differing protein expression. Caspase-9, an initiator caspase, undergoes alternate 
splicing via SRp30a, causing two splice variants - caspase-9a (pro-apoptotic) and caspase-9b 
(anti-apoptotic) [13-15]. The variant expression is a determinant of the activation of the intrinsic 
pathway to ensure cellular death.  
 
The health care policies in SA have not been beneficial to all South Africans especially in the 
rural areas [6]. The quality of health care is relatively low as well as access to these services are 
inadequate. Traditional medicine has therefore been the only access for maintenance and 
management of various diseases. Moringa oleifera (MO) commonly known as Drumstick tree is 
consumed widely in SA and is used in traditional medicine [16, 17]. Almost all parts of the tree 
are used in traditional treatments, however the leaves possess high levels of vitamins, amino 
acids, proteins and antioxidants [18, 19]. There are many bioactive compounds such as 
niazimicin, gallic acid, glucosinolates and isothiocyanates present in the extract which possess 
anticancer and anti-inflammatory properties [16, 20, 21]. Traditional healers in SA, utilise MO 
as part of their treatment of various ailments however their mode of action have not been 
elucidated.  
 
Nanoparticles (NP’s) are showing huge promise in cancer therapy [22] because they have 
characteristic properties of being very small (1-100nm). Metals such as gold (Au) are readily 
available for use in the synthesis of NP’s. These NP’s can be synthesised using plant extracts 
such as MO - in a cost effective and environmentally friendly synthesis.  
 
Currently there are no reports for the anti-cancer effects of MO leaf extract (MOE). In addition, 
the use of MOE to synthesise novel gold nanoparticles (AuNP’s) have not been conducted. This 
study determined the antiproliferative and apoptosis inducing effects of MOE and its 
synthesised AuNP’s (MLAuNP) on human carcinomas - A549 lung and SNO oesophageal cancer 
cells in vitro. The study provides a biochemical mechanism underlying the use of SA’s 









RESEARCH RATIONALE, AIM, HYPOTHESIS AND OBJECTIVE 
 
Research rationale 
Despite the major advances in medicine, many people still depend on natural remedies. Due to 
SA’s limited healthcare services especially in our rural areas, traditional medicine has been the 
only access to treatment of various diseases. MO has both nutritional and medicinal properties 
and is used traditionally to treat malnutrition, diabetes mellitus - type 2, cardiovascular and liver 
diseases [16, 23]. MO trees grow well in both rural and urban areas and its leaves are readily 
available for use. Traditional healers in SA therefore utilise MO as part of their treatment 
regime. Cancer mortality rates are increasing and global burden is expected to increase even 
further [8]. MOE possesses anticancer properties and can be used to synthesise AuNP’s 
however their exact pharmacological action has not been investigated and established.  
 
Aim 
The aim of the study was to determine the antiproliferative properties of MOE (crude aqueous 
extract) and its synthesised AuNP’s (MLAuNP) (exposed singly) in selected cancerous cell lines. 
 
Hypothesis 
MOE and MLAuNP possess antiproliferative properties in cancerous cells in vitro with minimal 
cytotoxic effects on normal healthy cells.   
 
Objective 
The objectives of this study were designed to assess the antiproliferate effects of MOE and 
MLAuNP (exposed singly) on carcinoma cell lines (A549 lung and SNO oesophageal cancer cells) 
to determine whether it: 
1) Increased oxidative stress and apoptosis in A549 lung cancer cells 
2) Increased oxidative stress and apoptosis in SNO oesophageal cancer cells 
3) Increased apoptosis in SNO oesophageal cancer cells and influenced 
oncogenes, tumour suppressor genes and caspase-9 splice variants to induce 













1.1. Moringa oleifera - ‘The tree of life’ 
Ancient medicinal systems have extensively utilised natural resources such as trees and plants in 
alleviating, managing and treating a variety of ailments. The evolution of mankind has therefore 
depended tremendously on these ancient traditional medicinal systems. As nature provided a 
storehouse of natural remedies, their traditional uses have been passed on from generations 
having a positive impact on human health.  
 
A versatile tree with a vast range of therapeutic potential, Moringa oleifera (MO), is an 
indigenous tree to India but found widely in other parts of the world, including SA [20]. This 
multipurpose and rapid-growing tree is cultivated for medicinal and industrial purposes 
increasing its utilisation among many communities (Figure 1.1) [16]. Often known as the ‘Tree 
of life’, it is also referred to as the Drumstick tree, Soanjna and Murungai [16, 17]. Moringa 
oleifera leaves, flowers, seedpod (drumstick), seeds and bark are edible and has been part of  the 
conventional diet of many communities [20, 24].  
 
 
Figure 1.1 A branch of leaves from the Moringa oleifera tree [25] 
 
1.1.1. Taxonomy 
Moringa oleifera, a natural reservoir for nutrition and medicine, is used in many traditional 
therapies [26]. The tree has been scientifically classified accordingly into the Kingdom - 
Plantae, Division - Magnoliphyta, Class - Magnoliopsida, Order - Brassicales, Family - 






In both rural and urban areas, MO trees are grown and utilised for nutritional as well as 
medicinal properties. The various parts of this tree are consumed and utilised on a regular basis. 
Figure 1.2 shows images of the MO tree with various parts readily available as food sources as 
well as traditional medicinal use.  
 
 
Figure 1.2 Images of the Moringa oleifera tree found locally [MO leaves (A), MO flowers (B),  
MO seedpod and seeds (C)] 
 
1.1.2. Habitat 
Indigenous to the Indian subcontinent, MO is also found in warmer regions including SA. The 
tree grows well in dry loamy soil which is slightly alkaline [24], however it is very adaptable to 
varying conditions. It thrives in dry to moist climates, with rainfall ranging from 25-300cm 
annually with temperatures of 19-28°C [25].  
 
1.1.3. Traditional herbal medicine  
In developing countries such as SA, traditional medicine has played a vital role in managing and 
treating various diseases [27]. According to the World Health Organisation (WHO), traditional 
medicine is defined as ‘health practices, approaches, knowledge, and beliefs incorporating plant, 
animal and mineral based medicines, spiritual therapies, manual techniques and exercises, 
applied singularly or in combination to treat, diagnose and prevent illnesses and, maintain 
wellbeing’ [28]. A wide range of plants have been utilised in traditional medicine to treat a 
variety of ailments even those non-responsive to western medicine. In SA, approximately 75% 





extensively used as almost all parts of the tree namely the leaves, seedpods (drumstick), seeds, 
flowers and bark possess medicinal properties. The rural areas of SA often have limited 
financial resource as well as health care services therefore many people rely on traditional 
healers for treatment of which the MO medicinal tree forms part of their treatment regime. 
  
1.1.4. Nutritional value of Moringa oleifera 
All parts of the tree possess medicinal properties however MO leaves display high nutritional 
value as they contain high levels of vitamin A, vitamin C, potassium, proteins, calcium and iron 
[18]. Studies show that the concentration of vitamin A is higher than carrots (four times), 
vitamin C is higher than oranges (seven times), calcium and protein is higher than milk (four 
and two times respectively) and potassium is higher than bananas (three times) [29, 30]. This 
high nutritional value of MO is particularly important in developing countries where 
malnutrition is prevalent.  
 
1.1.5. Biological properties 
The Drumstick tree displays many biological properties as it is used in folk medicine for the 
treatment of inflammation, diabetes mellitus - type 2, cardiovascular and liver disease [18, 23, 
31, 32]. The leaf extract is used to treat hypertension and displays hypoglycaemic, 
hypocholesterolaemic, antitumour, antioxidant and hepatoprotective properties [30, 33]. These 
properties can be attributed to MOE’s constituents as it possesses a high indigenous source of 
vitamins and phytochemicals like carotenoids (β-carotene), alkaloids and flavonoids [20]. It is 
rich in amino acids such cystine, lysine, methionine and tryptophan [34, 35].  
 
1.1.6. Phytochemistry of Moringa oleifera 
Dietary intake of plants, fruits and vegetables are beneficial, improving overall health [36]. A 
poor diet has been associated to 30-40% of cancer development [37]. Increasing the dietary 
intake of plants, fruits and vegetables have shown to lower the incidence of cancer. The lowered 
cancer incidence is due to the chemopreventive effects of phytochemicals of which these natural 
products contain [36, 37]. They affect the tumour microenvironment, cell proliferation and 
apoptosis displaying its anticancer effect. Epigallocatechin-3-gallate (isolated from green tea) 
and resveratrol (isolated from grapes and red wine) are examples of phytochemicals which have 
been identified to display anticancer effects and have entered clinical trials. 
 
Phytochemicals have three structural classes namely glucosinolates (contains β-thioglucoside N-





phenolic acids (contains benzoic acid and cinnamic acid with hydroxyl groups) [38]. The MO 
leaves contain glucosinolates which has a benzyl-glycoside group linked to a single carbon. The 
enzymatic hydrolysis of glucosinolates results in the formation of isothiocyanates, thiocyanates 
or nitriles. Myrosinase (thioglucoside glucohydrolase) is an enzyme responsible for cleavage of 
the thio-liked glucose in glucosinolates [39]. The remaining aglycone rearranges to form 
isothiocyanates. Glucosinolates are also converted to isothiocyanates by host gut microbiota. 
Isothiocyanates from MO leaves are similar to those from crucifers however they are present at 
higher concentrations and more chemically stable thereby increasing their anticancer potential.       
 
Phytochemical properties of MO contributes to its action against diseases [20]. It contains a rich 
source of rhamnose, glucosinolates and isothiocyanates. The compounds present in MO are 
responsible for its anticancer effects. These include 4-(α-L-rhamnopyranosyloxy) benzyl 
glucosinolate, 4-(α-L-rhamnopyranosyloxy) benzyl isothiocyanate, benzyl isothiocyanate and 
niazimicin (Figure 1.3). The leaves contain quercetin-3-O-glucoside and kaempferol-3-O-
glucoside which play a role in antioxidant defence by scavenging free radicals and reducing 
oxidative stress [16]. The bioactive compound, niazimicin, can be utilised as agent for 
chemoprevention [40-42]. It also has antibacterial, hypotensive and bradycardiac activity [43]. 
Fractional studies of MO leaf extract (MOE) showed it is composed of flavonoids, hyperosid, 
rutosid, terpenoids, oleanoic acid and β-sitosterol which attributed to its antioxidant properties 
[44]. Chlorogenic acid, gallic acid, ferulic acid and ellagic acid are present in the leaves [25, 
38]. MO leaves also contain nitrile glycosides, niaziridin and niazirin [45]. These compounds 
increase bio-availability of drugs which enables a reduction in drug associated toxicity and 










Figure 1.3 The phytochemical constituents of MO 4-(α-L-rhamnopyranosyloxy) benzyl 
glucosinolate (A), 4-(α-L-rhamnopyranosyloxy) benzyl isothiocyanate (B), benzyl 
isothiocyanate (C) and niazimicin (D) [20] 
 
Several studies on MO used solvent extracts to assess their biological activities [40, 46-49]. 
Solvent extraction isolates bioactive compounds with methanol, ethanol, acetone, ethyl acetate, 
hot, cold water and buffers [40, 46-50]. Anticancer drug chemical structures have hydrophobic 
groups which make them insoluble in water [50, 51]. Intravenous administration of poorly 
soluble drugs results in poor absorption. This causes precipitation of the drugs with severe 
complications including embolism and respiratory system failure. Therefore increasing water 
solubility can be beneficial for anticancer agents. Limited scientific evidence is available for the 
use of aqueous leaf extract of MO as an anticancer agent.  
 
1.1.7. Pharmacological action of Moringa oleifera    
Antioxidant and anticancer properties of MO are known to induce apoptosis and disrupt 
proliferation of cancer cells. Previous studies have shown MOE to inhibit lipid peroxidation by 
scavenging free radicals thus reducing oxidative stress. MOE also offered protection against 
oxidative DNA damage [52]. The bioactive components of MO have shown to be effective in 
Burkett’s lymphoma as it inhibited the activation of early antigen of phorbol ester (TPA)-
induced Epstein-Barr virus [53]. Cytotoxic activity of MOE was seen in human hepatocellular 
carcinoma cells. Asare et al., 2012 assessed MOE’s cytotoxic and genotoxic effects using 







Toxicology studies on MOE also showed that the aqueous leaf extract is relatively safe when 
administrated orally [54]. Acute toxicity tests were conducted on male Wistar albino mice and 
showed no significant changes in biochemical and haematological markers rendering the 
aqueous leaf extract to be relatively safe. Radiotherapy has been used in treatment of cancers 
but has many side effects [55]; MOE counteracted these side effects, demonstrating a protective 
effect. An ethanol-water extract of MOE were used in HeLa cells to determine the cytotoxic 
effects [56]. HeLa cells were exposed to the extract for 48h which caused a dose-dependent 
decline in cell viability. MOE contains a wide range of phenolic compounds thereby causing a 
decline in cell viability. The effect of MOE and seedpod (drumstick) extracts in vitro and in vivo 
were investigated [57]. The aqueous extracts decreased malondialdehyde levels and increased 
glutathione levels displaying its antioxidant potential. The effects of MOE on human 
macrophages after exposure to cigarette smoke extract were investigated and showed that the 
ethyl acetate fraction decreased tumour necrosis factor alpha (TNF-α), interleukin (IL)-6 and IL-
8 response [58]. It also decreased RelA gene expression responsible for inflammation. The 
decrease in cytokine production results in decreased tissue damage.  
 
The bioactive compound, chlorogenic acid, has shown to induce apoptosis in Bcr-Abl+ chronic 
myeloid leukaemia [59]. There was an increase in reactive oxygen species, mitochondrial 
dysfunction and subsequent release of cytochrome c which led to the activation of caspases and 
the induction of apoptosis in the leukaemic cells. Ovarian cancer is now becoming resistant to 
treatment with cisplatin therefore alternate therapies are being investigated [60]. Kaempferol, 
also a bioactive compound, have shown potential in ovarian cancer as it decreased vascular 
endothelial growth factor (VEGF) in the cancer cells. Kaempferol also sensitised the ovarian 
cancer cells to cisplatin treatment. Kaempferol and cisplatin worked synergistically to inhibit a 
member of the ABCC family, ABCC6, which are membrane transport proteins. The ABCC 
family of proteins cause the efflux of anticancer drugs leading to drug resistance. Kaempferol 
and cisplatin also synergistically inhibited c-myc mRNA levels thereby inducing apoptosis. 
Although natural products and their bioactive components are showing huge potential in cancer 
therapeutics, further investigation into cancer cell target therapy is necessary.   
 
1.2. Nanoparticles  
Nanoscience has revolutionised modern science and medical research as it is being utilised to 
improve the quality of life [22]. Nanotechnology is a novel approach to medicine as it enables 
early detection, diagnosis and treatment of diseases [61]. Nanoparticles have their potential use 





determined [62]. Metals such as gold are readily available. AuNP’s were developed as they are 
biocompatible and stable with therapeutic application in various diseases such as Rheumatoid 
arthritis, Diabetes mellitus - type 2, Hepatitis B, HIV, TB and Alzheimer [63]. Due to the 
size of these nanoparticles (approximately 10 thousand times smaller than the human cell) - they 
are able to interact with cell molecules both on the surface and intracellularly [64]. 
Nanoparticles are stabilised chemically or via the use of plants [22]. The use of plant extracts in 
the synthesis of nanoparticles can be cost effective and advantageous in large scale production. 
It is a good alternative as chemical synthesis involves toxic chemicals which can be detrimental 
to the environment [65]. Nanoparticles facilitate the recognition of the cancer cell, binding to it 
and ultimately carrying out its therapeutic effect with minimal or no effect on normal healthy 
cells.  
 
The one-pot green synthesis technique used for the synthesis of nanoparticles involves a redox 
reaction which is facilitated by plant extracts [65, 66]. In addition, the green synthesis of NP’s 
are also facilitated by fungi, bacteria, yeast and algae [67]. They have the ability to cause the 
reduction of metal ions into NP’s. Plant extracts such as leaves and flowers are favourable for 
the synthesis of NP’s as it does not require any preparation or isolation, in addition to the low 
cost associated with its cultivation [22, 68]. Plant extracts such as MOE contains many 
bioactive compounds such as phenolic acids and flavonoids [57, 69]. Flavonoids play a role in 
chelation and the reduction of metal ions for the synthesis of nanoparticles [67]. This occurs due 
to their conversion from enol- to keto- form which releases a hydrogen atom. It has been shown 
that MO seedpod causes the reduction of chloroauric acid which resulted in the synthesis of 
AuNP’s [69]. The AuNP’s protected HepG2 cells against the toxicity associated with the 
exposure to acetaminophen and carbon tetrachloride. Gold nanoparticles have been synthesised 
using "green" capping agents that are derived from medicinal plants such as Hibiscus rosa 
sinensis and Ocimum sanctum [70, 71].     
 
Silver (Ag) nanoparticles were synthesised by Albizia adianthifolia leaf extract. It caused the 
redox reaction - Ag+ ions were reduced to Ag0 [66]. The silver nanoparticles induced A549 lung 
cancer cell death [72]. A one-pot green synthesis technique was also used for the synthesis of 
gold nanoparticles mediated by Moringa oleifera flower extract (MFAuNP). It also showed the 
redox reaction by which Au+ ions were reduced to Au0 [65]. The synthesis of silver 
nanoparticles using MO aqueous leaf extract for the reduction of the silver ions showed 
potential use of MO in the synthesis of nanoparticles [22]. Therefore green synthesis of 





1.2.1. Gold nanoparticles - Emerging benefits in medicine 
Nanoparticle sizes range between 1-100nm and are showing promise in cancer therapeutics [73, 
74]. Gold nanoparticles (AuNP’s) have been used in diagnosis, drug delivery and treatment 
however limited scientific evidence is available as an anticancer agent. Gold is biologically inert 
facilitating its biocompatibility and non-cytotoxicity [75, 76]. In addition, according to the 
shape and size of the synthesised AuNP’s, they are easily distributed to various parts of the 
body further enhancing their therapeutic effect. AuNP’s induced DNA damage, cytokinesis 
arrest and apoptosis in human oral squamous cell carcinoma showing potential as an anticancer 
agent [62]. AuNP’s are favoured over silver nanoparticles as they are more stable, 
biocompatible and the synthesis is cost-effective and environmentally friendly [74]. AuNP’s can 
enter the cell and bind strongly to amine and thiol groups [77]. AuNP’s have been utilised in 
medicine as there are minimal side-effects seen in patients [65]. In addition, AuNP’s have many 
diagnostic applications [78]. AuNP’s have a high surface area which enable them to bind to 
their targets efficiently. They are utilised in diagnostics due to their colour change upon 
aggregation for the detection of nucleic acid sequences. They also used as selective nanoprobes 
and signal enhancement for electrochemical methods of diagnosis.  
 
MFAuNP has been synthesised (Figure 1.4) [65]. MFAuNP induced a dose-dependent decline in 
A549 cell viability with minimal effect on normal healthy peripheral blood mononuclear cells 
(PBMCs). MOE can also be used for the synthesis of AuNP’s (MLAuNP) as it causes the 
reduction of chloroauric acid producing stabilised gold nanoparticles [79]. The AuNP’s 
produced were 20-60nm in size and stable up to 30 days. This environmentally friendly 








Figure 1.4 An example of gold nanoparticles mediated by Moringa oleifera flowers [65] 
 
Nanoparticles induce a variety of cellular responses [80]. Gold nanoparticles selectively target 
cancer cells as citrate-capped AuNP’s selectively targeted and induced apoptosis in human lung 
epithelial cells (A549) without an effect on BHK21 kidney cells and HepG2 liver cells [81]. 
Similarly it has been shown that citrate and 11-mercaptoundecanoic acid (11-MUA)-coated 
AuNP’s induced DNA damage in HepG2 cells [82]. AuNP’s mode of action depends on the 
size, shape, charge and surface conjugation [80]. Therefore different cancer cell types will 
respond differently to AuNP’s. Positively charged nanoparticles remain longer in the blood 
stream and are advantageous for an intravenous route of administration [83]. The conventional 
mode of administration of anticancer drugs is intravenously. Oral administration has been used 
for the delivery of drugs and this mode of administration has been used for chitosan 
nanoparticles. In addition, delivery of nanoparticles to the lungs can be conducted via 
inhalation. Nanoparticle bioavailability is a concern as investigations on rats showed that the 
size of the nanoparticle determined its distribution in the body [84]. AuNP’s size of 10nm had a 
widespread distribution whereas AuNP’s sizes 50-250nm where only distributed to the blood, 
spleen and liver. Nanoparticles, in general, function by inducing oxidative stress, increasing 
reactive oxygen species and decreasing antioxidants to create an imbalance of cellular redox 







1.3. Oxidative stress 
The mitochondrion, an energy producing intracelluar organelle with a double membrane [85], 
contains its own circular  deoxyribonucleic acid (DNA) [86]. The energy produced [adenosine 
triphosphate (ATP)] is via oxidative phophorylation. The inner mitochondrial membrane 
consists of five complexes (I-V) (Figure 1.5) which are responsible for oxidative 
phosphorylation. The mitochondria are vital in ATP generation, reactive oxygen species (ROS) 
formation and regulation of apoptosis.    
 
Oxidative stress, an imbalance between ROS, reactive nitrogen species (RNS) and antioxidant 
systems i.e. glutathione (GSH), catalase (CAT) and superoxide dismutase (SOD) levels leads to 
apoptosis [87]. ROS has an unpaired electron rendering them unstable and are produced during 
metabolic processes. When oxidative stress exceeds the antioxidant capacity of the cell - then 
macromolecules such as lipids, protein and DNA are oxidised by ROS [85]. The mitochondrion 
is the main source of production of ROS (Figure 1.5) [88]. ROS production is increased when 
the mitochondrial membrane potential is affected. The mitochondrial complex I releases 
superoxides in the matrix. The release of superoxides into the matrix and intermembrane space 
is also via complex III. The cell responds to increased ROS production by elevating antioxidant 
levels. The antioxidant, manganese SOD converts superoxides to hydrogen peroxide (H2O2) 
which is further converted to water by glutathione peroxidase (GPx) [89]. However when this 
does not occur H2O2 reacts with transition metals via the Fenton reaction to produce highly 
reactive hydroxyl radicals. ROS produced near membrane phospholipids leads to peroxidation 
of polyunsaturated fatty acid molecules leading to lipid peroxidation [87]. ROS also causes 
damage to proteins and DNA. The production of ROS can occur via mitochondrial respiration, 






Figure 1.5  The electron transport chain found on the inner mitochondrial membrane (A) and the 
production of reactive oxygen species (B) [89] 
 
When nitric oxide (NO•), nitroxyl anion (NO-) and nitrosonium cation (NO+) further exceeds the 
antioxidant capacity, it results in nitrosative stress [90]. Superoxides can react with nitric oxide 
to produce peroxynitrite [85, 91, 92]. Peroxynitrite targets thiol groups found in GSH. GSH, an 
important antioxidant, scavengers free radicals and reduces oxidative stress [93]. Present at high 
levels in the cell ranging from 1-10mM and 10-30µM in plasma, the active form, reduced GSH 
maintains the cellular redox milieu [9]. GSH is a tripeptide comprising of glycine, cysteine and 
glutamate.  
 
Reduced GSH forms from glutathione disulphide (GSSG) via a redox reaction catalysed by 
glutathione reductase (GSR) which utilises NADPH as a cofactor [9, 94-96]. In addition, GSH 
can become oxidised back to GSSG (catalysed by GPx) maintaining the redox balance. During 
oxidative stress, there is an imbalance between ROS, RNS and the antioxidant system. Also 
during oxidative stress the GSH: GSSG ratio is decreased.  
 
Nuclear factor - erythroid 2 p45 - related factor 2 (Nrf2) is a transcription factor that offers 
protection against oxidative insult [96-98]. When there is oxidative stress, Nrf2 dissociates from 
Kelch-like epichlorohydrin-associated protein 1 (Keap1) and translocates to the nucleus due to 





binding to antioxidant response element (ARE) in promoter regions of antioxidant genes. In 
mice, changes in Nrf2 resulted in oxidative damage and inflammation. Nrf2 regulates GSH 
homeostasis by regulating biosynthesis as well as the cysteine/glutamate exchange transporter. 
Intracellular GSH levels are thus maintained by the cysteine influx by the transporter.    
 
Cancer cells have higher metabolic activity with increased energy demand [100]. With an 
enhanced metabolic activity, ROS levels increase which can either stimulate metabolic 
pathways or if severe can induce oxidative damage. An adaptive response to oxidative damage 
is the up-regulation of antioxidants and cytoprotective genes. However, when these are unable 
to offer protection, it leads to apoptosis [85].  
 
1.4. Apoptosis - Mechanism of cell death 
Apoptosis or programmed cell death is a vital process in embryonic development and tissue 
homeostasis and is regulated by aspartate-specific cysteine proteases (caspases) [9, 10, 53]. The 
progression of apoptosis is due to signal cascades. Apoptosis occurs through two pathways 
namely: death receptor - mediated procaspase - activation pathway (extrinsic pathway) and 
mitochondrion - mediated procaspase - activation pathway (intrinsic pathway). Homeostasis is 
maintained by following a process of cell growth, division and death. This ensures a healthy 
state by regulating cell number and tissue size [11]. Cells that threaten homeostasis are signalled 
for cell death. Abberation to this process results in the initiation of cancer as abnormal cells are 
not removed and continue to proliferate. 
 
1.4.1. Morphology of apoptosis 
When apoptosis is induced, the cell undergoes characteristic morphological changes and result 
in cell shrinkage, membrane blebbing, cytoskeletal disruptions and chromatin condensation 
(Figure 1.6) [101-103]. Nuclear shrinkage and budding occurs as the nuclear lamins are cleaved 
[11, 104]. The change in morphology of the cell is due to the cleavage of cytoskeletal proteins 
which include gelsolin and fodrin; p21-activated kinase 2 (PAK2) is responsible for the cellular 
blebbling.  
 
Phosphatidylserine (PS) externalisation occurs as PS translocates from the inner leaflet to outer 
plasma membrane which is an early marker of apoptosis [105]. The cell loses its membrane 
phospholipid asymmetry. It has been shown that PS externalisation occurred in apoptotic 
lymphocytes and this feature was not seen in normal healthy lymphocytes [106]. PS 





Chromatin margination and nuclear fragmentation by endonuclease occurs to degrade the DNA 
[102]. The cell breaks down into smaller membrane-bound apoptotic bodies which become 
easier to be phagocytosed by the macrophages [9]. This prevents damage to neighbouring cells 
and the induction of inflammation.  
 
 
Figure 1.6 The morphological changes occurring during cell death [103] 
 
1.4.2. Mediators of apoptosis - Caspases 
Caspases play a vital role in apoptosis. Caspases are enzymatically inert zymogens which 
comprise of three domains namely an N-terminal prodomain, a p20 and p10 domain [11]. There 
are three main mechanisms of activation for these molecules which include activation by 
upstream caspases, induced proximity and association with a regulatory subunit. The cleavage 
of the zymogen between the prodomain and p20 domain or between the p20 and p10 domain 
leads to the activation of the caspases.  
 
Once upstream initiator caspase-8 and caspase-9 becomes activated, they signal for downstream 
effector caspase-3/7 to be activated [11]. The initiator caspases are activated via protein-protein 
interactions and induce the apoptotic mechanism. When the death receptor is stimulated, upon 
the binding of ligands to its corresponding receptors, it results in the aggregation of procaspase-





Caspase-9 activation is more complicated as it requires other regulatory subunits such as 
apoptotic protease activation factor-1 (Apaf-1), cytochrome c (cyt c) and ATP to form an 
apoptosome. Caspase-8 and caspase-9 are the mediators of the two apoptotic pathways.   
  
1.4.3. Apoptotic pathways 
1.4.3.1. Death receptor - mediated procaspase - activation pathway 
The extrinsic pathway of apoptosis occurs via two ligands namely CD95 (Fas) and TNF-α 
(Figure 1.7) [10]. The Fas or TNF ligand binds to its corresponding receptor, Fas-associated 
death domain (FADD) or TNFR-associated death domain (TRADD) respectively which leads to 
the activation of the death domain. The death-inducing signal complex (DISC) is formed and 
activated leading to the recruitment of many procaspase-8 molecules. The induced proximity 
causes procaspase-8 cleavage and activation [11]. Caspase-8 contains a death effector domain 
(DED) and can be inhibited via FADD-like interleukin-1β-converting enzyme (FLICE)-
inhibitory protein (c-FLIP). The caspase-8 activation directly leads to the activation of 
executioner caspase-3/7 or signals apoptosis via the mitochondria. It does this by cleaving a pro-
apoptotic molecule BH3-interacting domain death agonist (Bid) which is found in the cytosol 
and translocates as truncated Bid (tBid) to the mitochondria. The mitochondrion is targeted as 
tBid binds to cardiolipin, a mitochondrial specific lipid, through its helices 4-6 [107]. Its active 
form, tBid, is responsible for triggering the mitochondrial release of cyt c thus leading to cell 
death.  
 
1.4.3.2. Mitochondrion - mediated procaspase - activation pathway 
When cellular DNA is damaged or there is an increase in reactive oxygen species, the cell 
induces apoptosis via the mitochondria (Figure 1.7) [10]. A pro-apoptotic molecule from the 
Bcl-2 family (Bax, Bad, Bid), which localises in the cytoplasm, translocates to the 
mitochondrial outer membrane and binds to voltage-dependent anion channel (VDAC) and 
influences its activity [11, 108]. The VDAC protein then forms a subunit of the mitochondrial 
permeability transition pore (MPTP). When there is mitochondrial swelling, changes in ion 
channels and depolarisation of the mitochondrial membrane, it results in the opening of MPTP 
releasing cyt c into the cytoplasm and together with ATP, Apaf-1 and procaspase-9 forms an 
apoptosome. The interaction of caspase activation and recruitment domain (CARD) on the N-
terminal of Apaf-1 and the prodomain of procaspase-9 leads to the activation of caspase-9. This 
activates executioner caspase-3/7 resulting in apoptosis as well as a positive feedback 






Anti-apoptotic molecules from the Bcl-2 family include Bcl-2 and Bcl-xL [11]. They contain 
four Bcl-2 homology (BH) domains and a C-terminal hydrophobic tail. The proteins localise on 
the outer surface of the mitochondria thereby preventing apoptosis and ensuring cell survival. 
They bind to prevent the oligomerisation of pro-apoptotic molecules such as Bax [107]. Thus, 
the regulation between pro- and anti- apoptotic molecules is a determinant of cellular fate. 
 
There are regulators of the mitochondrial apoptotic pathway such as heat shock proteins (Hsp) 
which act as chaperones [109]. Upon acute or chronic stress, proteins become misfolded and 
Hsp are then expressed to restore protein homestasis. It possess cytoprotective effects ensuring 
cell survival. Under normal physiological conditions, Hsp expression is fairly low. Hsp prevents 
the execution of apoptotic cascade as Hsp27 and Hsp70 sequests cyt c and Apaf-1 respectively. 
This prevents the apoptosome formation and the subsequent caspase-3/7 activation. In 
cancerous cells, Hsp expression is high further preventing the progression of apoptosis. This can 
be a potential target in chemotherapy. 
 
Inhibitor of apoptosis proteins (IAP’s) contain baculovirus IAP repeat (BIR) domains which 
target, bind and inhibit caspase-3/7 activity further preventing the execution of apoptosis [11, 
107]. Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis binding 
protein with low pI (Smac/DIABLO) is concurrently released from the mitchondria with cyt c 
and antagonises IAP’s thus ensuring the execution of apoptosis [9, 110]. Smac/DIABLO binds 
to X chromosome encoded IAP (xIAP) at BIR 2 and 3 domain, the bindng site for caspase-3/7 
thus inhibiting its function [107]. Through Smac/DIABLO functionality, the mitochondria 
enables the effective progression of the apoptotic cascade. 
 
Cytochrome c (cyt c) is a key molecule in the mitochondrion as it is a water-soluble component 
of the electron transport chain [107, 111]. When cyt c is released during apoptosis, the electron 
transport chain, ATP synthesis and mitochondrial membrane potential is affected. In the 
electron transport chain, cyt c is responsible for transferring electrons from cytochrome c 
reductase (complex III) to cytochrome c oxidase (complex IV). During this process water is 
formed by the reduction of oxygen. Due to the release of cyt c, it affects this step in the electron 
transport chain thus leading to the formation of ROS. An increase in ROS results in oxidative 








Figure 1.7  Caspases and its regulating factors in the apoptotic pathways [9] 
 
1.5. Messenger ribonucleic acid (RNA), protein synthesis and alternate splicing of caspase-
9 
The Central Dogma of Biology is a process that is important for all living cells. It involves the 
replication of DNA and conversion of important genetic information into protein. Messenger 
RNA (mRNA) transfers this genetic information from the cell nucleus to ribosomes [112]. It is 
complementary to the gene sequence in DNA. Genetic information is coded by DNA and the 
ribosomes are found in the cytoplasm of cells where it utilises the genetic information as a 
template for the synthesis of proteins. The mRNA becomes translated to protein, stored or can 
be degraded [113]. The synthesis of proteins is important in many physiological processes and 
aberrations to the synthesis can result in disease. In addition, alternate pre-mRNA splicing 
enables a diverse expression of protein isoforms from a single gene [114]. These proteins often 
have differing functionality. Approximately 90% of human genes have alternate spliced 
isoforms resulting in diverse protein expression [114, 115]. Under normal physiological 
conditions, inappropriate alternate splice forms are removed via the nonsense-mediated mRNA 





maintained to ensure cell survival. Therefore targeting alternate pre-mRNA splicing can be 
beneficial in cancer therapies.  
 
A human gene is made up of coding regions (exons) and non-coding regions (introns) [114]. 
Alternate pre-mRNA splicing removes introns and joins together exons. The newly spliced 
mRNA leaves the nucleus and enters the cytoplasm for translation into protein. Through 
alternate pre-mRNA splicing, various mRNA are produced which is translated into proteins 
with various biological effects. RNA trans-acting splicing factors are responsible for activating 
alternate splicing in the cell. Serine/arginine-rich proteins (SR proteins) regulate the processing 
of pre-mRNA [13, 114]. 
   
Alternate splicing of caspase-9 produces two splice variants viz. caspase-9a and caspase-9b 
(Figure 1.8). SRp30a is an important RNA trans-acting factor for alternate slicing of caspase-9 
pre-mRNA [13]. The activation of caspase-9 gene pro-apoptotic function involves an increase 
in pro-apoptotic splice variant caspase-9a (exon 3, 4, 5, 6 cassette inclusion) with a decrease in 
anti-apoptotic splice variant caspase-9b (exon 3, 4, 5, 6 cassette exclusion). The caspase-9b 
competes with caspase-9a splice variant for binding to the apoptosome. Caspase-9b splice 
variant does not have the catalytic activity but has the interacting domains (CARD) [14]. Shultz 
et al., 2010 showed that through alternate splicing of caspase-9, ceramide was able to induce 
apoptosis in A549 lung cancer cells [14]. The regulation of the alternate splicing is vital in the 
interaction with APAF-1 for apoptosome formation and the downstream activation of effector 
caspase-3/7. Through the down-regulation of SRp30a, it induces the caspase-9b splice variant 
and halts the apoptotic machinery. It has been shown that MCF-7 cells were not able to undergo 
apoptosis when caspase-9b splice variant was expressed [116]. In addition, this expression also 
disrupted the apoptosome formation [117] conferring resistance irrespective of apoptotic stimuli 







Figure 1.8  Regulation of caspase-9 gene expression by alternate mRNA splicing in a normal 
cell (A) and tumour cell (B) [115] 
 
A member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, hnRNP L, is also a 
regulator of caspase-9 and has been implicated in the exclusion of the exon cassette thus 
favouring the caspase-9b splice variant expression [14] (Figure 1.8). Splice variant expression 
of caspase-9 is imperative for the induction and execution of the apoptotic cascade and the 
subsequent cleavage and inactivation of regulating proteins such as poly (ADP ribose) 
polymerase-1 (PARP-1).  
 
1.6. The role of poly (ADP ribose) polymerase-1 in apoptosis 
Certain cellular proteins are lysed by caspases during apoptosis. These proteins include PARP-
1. During apoptosis, caspases are activated and caspase-3 cleaves PARP-1 (Figure 1.9) [118, 
119]. PARP-1, a nuclear enzyme, is proteolysed to a 24 kDa N-terminal DNA-binding domain 
and an 89 kDa C-terminal catalytic fragment rendering PARP-1 inactive [120-122]. The N-
terminal DNA-binding domain has two zinc fingers [123]. The cleavage prevents cell survival 





apoptosis inducing factor (AIF) release from the mitochondria causing DNA damage and 
caspase-independent apoptotic cell death.   
 
PARP-1 responds to low levels of DNA damage by cleaving nicotinamide adenine dinucleotide 
(NAD+) to nicotinamide and ADP-ribose [123, 124]. ADP-ribose is utilised to form ADP-ribose 
polymers on nuclear proteins including endonucleases, topoisomerase and histones. PARP-1 
plays a role in DNA base excision repair, maintenance of the integrity of the genome thus 
ensuring cell survival [125]. PARP-1 has a high affinity to single-strand (ss) or double-strand 
(ds) breaks in DNA via the two zinc fingers and facilitates base excision repair [125, 126]. It 
recruits DNA repair proteins such as DNA ligase III, XRCC-1 and DNA polymerase β thus the 
cell is able to recover. However when there is cleavage of PARP-1, the 24 kDa fragment (the 
DNA binding domain which irreversibly binds to DNA strand breaks) inhibits DNA repair 
enzymes from accessing the damage sites preventing repair and cell survival function [127]. It is 
also seen that when there is DNA damage, the 89 kDa fragment is unable to be stimulated [124]. 
When there is an extremely high level of DNA damage, PARP-1 decreases NAD+ and the 
production of ATP substantially [123]. This ultimately leads to necrosis (Figure 1.9).  
 
 
Figure 1.9 Poly (ADP ribose) polymerase-1 response in cell survival and cell death [123]  
 
PARP-1 has been implicated in cancers as it plays a role in cell survival [123]. Current 
anticancer agents induce DNA damage however PARP-1 is also activated for DNA repair. 
Therefore, inhibiting PARP-1 activity can be a therapeutic target in cancer as it will delay the 
DNA repair response and facilitate apoptosis via tumour suppressor gene, p53, which also 







1.7. p53 - ‘The guardian of the genome’ 
p53, a tumour suppressor gene and transcription factor, is a regulator of the apoptotic cascade 
[119, 128]. A defective p53 gene is generally seen in more than 70% of cancers thereby 
affecting the cell cycle checkpoint resulting in cell proliferation [129]. p53 responds to a variety 
of stimuli such as ROS, DNA damage and lesions, inappropriate oncogene activation and 
anoxia. It also monitors telomere length.  
 
Cancer is genetically unstable with the loss of p53 function [130]. An assessment of the role of 
p53 in lung cancer, mice were injected with C8 fibroblasts containing either wild-type or mutant 
p53. The lungs were isolated within 2 to 4 hours and showed that lung macrometastases 
possessed the mutant p53 alleles. The loss of p53 function is the basis for metastasis and can be 
a therapeutic target. Previous studies have shown that lung and prostate cancers which contained 
mutant p53 gene resulted in cancer cell apoptosis via the introduction of the wild-type p53 
showing potential in gene therapy by p53 targeting [129]. Using a retroviral vector also showed 
potential in patients who were non-responsive to conventional chemotherapy. There are 
limitations to gene therapy as the mutant variant may be more dominant as well as sufficient 
copies of the gene needs to be delivered to target cells. Also, the differentiation between normal 
healthy cells and cancer cells is imperative. 
 
Under normal physiological conditions p53 is bound to Mdm2 rendering it inactive [128]. Upon 
stimuli viz. oxidative DNA damage, p53 becomes phosphorylated, releasing Mdm2, causing 
p53 activation (Figure 1.10). p53 then signals for cell cycle arrest by activating p21 which 
inhibits the cyclin-CDK complex and the progression from G1 to S phase in the cell cycle. The 
damaged cell undergoes repair and those cells which have irreparable damage are then signalled 
for apoptosis via the mitochondrial pathway. This prevents defective cells from continuing in 
the cell cycle resulting in tumour formation. If p53 function is lost, p21 gene is not transcribed 
to inhibit the cyclin-CDK complex thereby allowing increased cell cycle activity with 






Figure 1.10 Schematic model of the activation of p53 and its signalling pathway [129]  
 
Irreparable cells are signalled by p53 to undergo apoptosis via the mitochondria [128, 131]. 
Upon stimuli, p53 increases the transcription and activation of pro-apoptotic molecule Bax. Bax 
translocates from the cytoplasm to the mitochondria were it undergoes oligomerisation. It binds 
to the outer mitochondrial membrane causing mitochondrial depolarisation, opening of MPTP 
and subsequent release of cyt c into the cytoplasm. The formation of the apoptosome (cyt c, 
ATP, APAF-1 and procaspase-9) activates caspase-9 and downstream executioner caspase-3/7 
resulting in apoptosis. Therefore targeting p53 expression in cancers which have increased 
oncogene expression will ultimately lead to apoptosis and can be beneficial in therapy.         
 
1.8. Oncogenic role of c-myc 
Oncogenes are responsible for cell growth and proliferation leading to tumour formation [129]. 
Activated oncogenes initiates cancer and maintains a cell in its proliferative state therefore has 
been a target for anticancer therapies [132]. c-Myc is an oncogene involved in the process of 
tumourigenesis [133]. c-Myc belongs to the family of myc genes [134]. The myc family 
contains c-myc, L-myc and N-myc with neoplastic properties. c-Myc is made up of an N-
terminal regulatory and transactivational domain [135]. This domain contains Myc-box motifs, 
MBI and MBII. There is a C-terminal basic helix-loop-helix leucine zipper and a DNA-binding 
domain. It is responsible for tumour formation because when activated [134], there is an 
increase in cell proliferation. Generally c-myc is under homeostatic control however in human 
cancers, translocation from chromosome 8q24 to chromosome 2, 14, or 22 in B cells results in 





[129]. Lung, breast and colon cancers express high levels of c-myc. Approximately 70% of 
human cancers have dysregulated c-myc expression [136]. The gene encodes transactivating 
factors controlling cell differentiation, proliferation and apoptosis [134, 137]. The increased 
stability of c-myc has shown to induce carcinogenesis [138].   
 
Nutrients, growth factors and mitogenic stimuli activate signal transduction pathways resulting 
in a phosphorylation cascade and the activation of c-myc. The RAS/RAF/MEK/ERK pathway 
phosphorylates myc at serine 62, stabilising it whereas glycogen synthase kinase 3β (Gsk3β) 
phosphorylates myc at threonine 58 (Thr58) which results in its destabilisation [138]. c-Myc is 
expressed in S-phase of the cell cycle and is tightly regulated [129]. In cancer there is 
overexpression of c-myc resulting in cell cycle progression. 
 
Chromosomal rearrangements and increased transcriptional pathways activate c-myc [139]. c-
Myc targets rate-limiting enzymes and is involved in ROS production. c-Myc is also involved in 
cell cycle as it causes G1 to S phase progression. It is able increase transcription of cyclins and 
reduces inhibitors of cyclin/CDK complexes. c-Myc inhibits p27 resulting in the activation of 
cyclin E/CDK2 complex. The decreased p27 has been noted in various cancers enabling cells to 
continue in the cell cycle. The Skp1/Cull/F-box (SCF) ligase complex ubiquitinates p27 for 
proteasomal degradation. c-Myc can further activate Cull in the complex which leads to the 
degradation of p27. Through the activation of the cyclin/CDK complex, c-myc is able to 
promote cell progression irrespective of the Rb checkpoint in the cell cycle.  
 
1.9. c-Myc/Skp2/Fbw7α pathway  
c-Myc stability and function is regulated by ubiquitin mediated pathways which include 
ubiquitin ligases [138]. The F-box ubiquitin ligases are S-phase kinase-associated protein 2 
(Skp2) and F-box and WD repeat domain-containing 7 (Fbw7) which recognise substrates for 
proteasomal degradation. They form subunits of the SCF-type E3 ligase [SCF (Skp1/Cull/F-box 
protein) complexes] [12] which is also involved in proteasomal degradation. In the SCF 
complex, the F-box proteins recognise the substrates and Cull ubiquitinates it for proteasomal 
degradation [138]. Skp2 and Fbw7 cause the ubiquitination and degradation of c-myc [138]. 
Fbw7 and Skp2 targets the MBI and MBII domains of c-myc respectively. Skp2 binds to MBII 
via the leucine-rich repeats which results in ubiquitination and degradation. In addition, c-myc 
increases Skp2 expression which also acts as a co-factor increasing c-myc’s transcriptional 






Skp2 also targets p27 and p57 involved in inhibiting cell cycle progression [140]. Through the 
downregulation of Skp2, it results in the accumulation of p27 therefore causing cell cycle arrest. 
Studies have shown that quercetin, curcumin and epigallocatechin-3-gallate possess anticancer 
effects by inhibiting Skp2 expression. It has been shown that Skp2 expression is increased via c-
myc activation in K562 myeloid leukaemia cells [141]. Bone marrow samples from chronic 
myeloid leukaemia patients had also shown the correlation. In addition, silencing of Skp2 
prevented c-myc’s inhibition of p27.  
 
The degradation of c-myc by Fbw7 requires additional steps [12, 138]. c-Myc is phosphorylated 
by Gsk3β at Thr58 which causes destabilisation. This further facilitates the degradation as Fbw7 
recognises the phosphorylated site in the MBI domain. The decreased expression of Fbw7 
confers drug resistance in cancers as Fbw7 can act as a tumour suppressor gene [140]. Fbw7 
have different isoforms α, β and γ which are located in the nucleus, cytoplasm and nucleolus 
respectively. Fbw7 is regulated by upstream genes including p53. 
 
The apoptosis inducing effects of bioactive compound wogonin on A549 cells were investigated 
[12]. Natural products and their bioactive compounds are showing potential in cancer therapies 
however their mechanism of action is required to be identified. Wogonin decreased A549 cell 
viability and increased the cleavage of PARP-1. In addition it caused the release of AIF and cyt 
c from the mitochondria which resulted in apoptosis via the intrinsic pathway. Studies show that 
the c-Myc/Skp2/Fbw7α pathway promotes cancer progression [12]. Wogonin decreased c-myc 
protein expression but not mRNA expression. Fbw7α and Gsk3β expression were also 
decreased. Wogonin decreased Skp2, HDAC1 and HDAC2 protein expression. The study 
suggested that wogonin had multiple anticancer effects and was able to induce apoptosis 
irrespective of the decreased Fbw7α expression. This is important especially in drug-resistant 
cancers therefore targeting the pathway will be beneficial for cancer therapies. The effects of 
Oridonin, a bioactive compound, on apoptosis in K562 myeloid leukaemia cells were 
determined [142]. Oridonin increased Gsk3β and Fbw7 which resulted in a reduction in c-myc 
expression and the induction of apoptosis in the cancer cells.  
 
1.10. Cancer 
Under normal conditions, a cell functions optimally thereby maintaining homeostasis in the 
body. During carcinogenesis, the physiological functioning of normal cells are disrupted leading 
to abnormal growth, proliferation and evasion of apoptosis [143]. Normal genes called proto-





uncontrollably by causing the formation of new blood vessels (angiogenesis) which allows 
nutrients to be delivered to the site of the tumour.  
 
There are also other factors which aids in cancer cell growth including sustaining a proliferative 
signal, evasion of growth suppressors, activation of invasion and metastasis, enabling 
replicative immortality and resisting cell death (apoptosis) (Figure 1.11) [143]. Cancer cells 
have a high metabolic rate and they utilise glucose through increased glycolysis (Warburg 
effect) [144]. Cellular metabolism is also affected as cancer cells dysregulates cellular 
energetics and evades the immune system [143]. Often there is dysregulation in oncogenes and 
tumour suppressor genes leading to carcinogenesis and therefore can be a potential target in 
chemotherapy. In SA, the rate of cancer incidence (lung and oesophageal cancer) is increasing 
[5]. The rate of incidence for lung cancer is 5.8 per 100,000 and oesophageal cancer is 32.7 per 
100,000 which is a growing concern. 
 
 
Figure 1.11 Cancer hallmarks [143] 
 
1.10.1. Lung cancer  
Lung cancer is a leading cause of death in many countries [119] and is the result of pollutants,  
toxins and cigarette smoking [87]. Non-smokers that are constantly exposed to tobacco smoke 
are at risk of developing lung cancer [145]. Surviving HIV positive individuals have a higher 
risk of lung cancer which previously has not been associated with the disease [8]. Diagnosis of 
lung cancer is expected to increase thus research into anticancer agents are imperative [146]. 





progression [147, 148]. Genetics play a role in predisposition to lung cancer as it affects 
absorption of tobacco smoke as well as its metabolism [145].    
 
Cancer in the lung originates from the basal epithelial cells [149]. There are two types viz. non-
small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It is estimated that 85% of 
diagnosed lung cancers are NSCLC. A549 cell line is a lung cancer cell line (NSCLC) derived 
from human pulmonary adenocarcinoma [150]. The cells were collected through explant culture 
from a Caucasian 58 year old male [151]. A549 cells retain the biochemical activities of human 
type II alveolar epithelial cells as it expresses cytokines and possesses cytochrome activity for 
biotransformation. A549 cells express the wild type of p53 and epidermal growth factor 
receptor (EGFR) gene and are therefore suitable for use in in vitro studies. 
 
Cisplatin is an anticancer agent used for treatment of lung cancer [152]. Cisplatin induces its 
anticancer effects by forming DNA adducts and subsequently activating apoptotic pathways via 
p53 [153]. Current first-line lung cancer therapy utilises cisplatin and gemcitabine [152]. 
Patients undergo a three week treatment regime. In addition, pemetrexed is also used in 
combination with cisplatin for first-line therapy. However there is resistance to cisplatin therapy 
as cancer cells reduce drug uptake, inactivate the drug and increase DNA repair [153]. In 
addition, cell survival pathways (phosphoinositide-3-kinase/Akt), anti-apoptotic molecules (Bcl-
2) are increased with a decrease in p53 expression which culminates in cisplatin resistance. 
Therefore effective alternative treatments are being investigated.    
 
1.10.2. Oesophageal cancer 
Oesophageal cancer (OC) is the most commonly diagnosed cancer in black men in SA. The 
increased prevalence is due to the presence of mycotoxins such as Fumonisin B1 in staple foods 
such as maize [154]. The risk factors associated to the development of OC includes ethnicity, 
diet and lifestyle. Family history, tobacco smoking and alcohol consumption also contributes to 
the aetiology of OC. Dietary deficiencies of magnesium, zinc, nicotinic acid and riboflavin have 
been seen to contribute to the development of the cancer [155]. The SNO cell line is an 
oesophageal cancer cell line derived from human oesophageal squamous carcinoma [156]. The 
cells were explanted from a Zulu 62 year old male.  It also retains biochemical activities and is 
therefore suitable for use in in vitro studies. 
 
Paclitaxel and 5-Fu are the first-line drugs used for oesophageal cancer therapy [157]. They are 





including alopecia, fatigue, and bone marrow suppression. Therefore alternate therapies are 
being investigated to inhibit cancer progression, improve drug efficacy, quality of life and 
increase positive outcome.  
 
1.11. Cancer progression  
Cancer cells evade the apoptotic cascade [53]. Mutation in genes that control important 
checkpoints and repair mechanisms results in the development of cancer [130]. Apoptosis plays 
an important role in homeostasis by removal of cells that have activated oncogenes or damaged 
DNA [129]. However in cancer, there is an increase in oncogene expression and loss of p53 
function thus cell cycle arrest does not occur further facilitating the progression of malignant 
cells into tumours. Lymphoma cancer cells over-express the anti-apoptotic molecule Bcl-2 and 
inhibit apoptosis. Cancer cells are able to synthesise decoy receptors of which CD95 (Fas) and 
TRIAL ligands bind to but are unable to signal the required apoptotic cascade. Chaperone 
proteins Hsp27 and Hsp70 are also elevated [109]. Exposure to cigarette smoke contains many 
compounds such as aromatic amines, N-nitroso compounds and polycyclic aromatic 
hydrocarbons which when in contact with the cytochrome P450 system becomes activated to its 
carcinogenic form [145]. This results in the formation of cancer and inhibition of the apoptotic 
cascade. Therefore targeting apoptosis in cancer cells prevents cancer progression and can be 
beneficial in therapy. 
 
1.12. Cancer therapy - targeting apoptotic pathways 
The apoptotic mechanism is a therapeutic target in cancer therapies [129]. In chemotherapy, the 
p53 response and the induction of apoptosis affects normal cells in addition to cancer cells thus 
resulting in alopecia (hair loss). Therefore an anticancer agent that specifically target and induce 
apoptosis in cancer cells with minimal effect on normal healthy cells is imperative. Cancer 
therapies such as cisplatin and paclitaxel target the mitochondria of cells and cause an increase 
in expression of Bax with a concomitant decrease of Bcl-2. This result in caspase activation and 
the execution of the apoptotic cascade. Research into chemotherapeutics has designed and 
developed mechanism based therapy to target various aspects of cancer cell survival and the 
induction of apoptosis [143]. However there are many limitations that are seen. 
 
1.13. Current limitations of cancer therapy - complementary and alternative medicine as a 
possible solution   
Cancer patients on anticancer therapies primarily experience several side effects. These include 





involves surgical removal, irradiation and chemotherapy [158]. In addition, the costs of current 
chemotherapies are rapidly increasing. Chemotherapy is non-specific with high toxicity levels 
and at times drug-resistant. Chemotherapy is toxic as there is limited aqueous solubility due to 
the diluent used to make up the treatment. It also lacks selectivity as current anticancer drug 
kills rapidly dividing cells which includes not only cancer cells but also normal healthy cells 
namely bone marrow and immune cells [75]. Also, multidrug resistance is a limiting factor as p-
glycoprotein transports anticancer drugs out of the cell preventing their activation and mode of 
action.  
 
Traditional medicine has benefitted many people by offering complementary and alternative 
treatment, providing relief from a plethora of ailments. Apoptosis is a useful marker for 
determining the potential of plants as an anticancer drug [159]. Medicinal plants have high 
biocompatibility, low toxicity and potent biological activity [50]. Therefore investigations into 
the anticancer activity of medicinal plants will be beneficial as they often display cytotoxic 
effects.       
 
1.14. MO and cancer - Therapeutic interventions 
Lung and oesophageal cancer still remains incurable therefore cost-effective alternate plant 
based therapies are actively being investigated [93]. MOE possess anticancer properties by 
increasing glutathione-S-transferase (GST) levels which can detoxify carcinogens [16]. MOE 
induced apoptosis in KB carcinoma cells [52]. Aqueous crude extracts of MOE possess 
anticancer properties in HeLa cancer cell line [160]. Although MOE and AuNP’s possess potent 
biological activities, there is no information with regards to its effects against lung and 
oesophageal cancer. Therefore scientific evidence pertaining to the effectiveness and 
mechanistic action of this medicinal plant and its synthesised AuNP’s requires investigation. 
 
1.15. Future prospects 
MOE and its synthesised AuNP’s show therapeutic potential in cancer. The synthesised AuNP’s 
further facilitate its uptake in cancer cells. South Africa has one of the highest HIV infection 
burdens globally and patients on antiretroviral therapy are prone to develop metabolic syndrome 
(dyslipidaemia, lipodystrophy and insulin resistance). MOE can be utilised in such patients 
since it has high nutritional, anticancer and immune-boosting activity. HIV also increase risk of 
secondary infections e.g., TB [7]. MOE also possess anti-bacterial properties and can therefore 





AuNP’s can be the next step in advance therapy thus SA’s traditional plant, MO, potentially has 
a positive impact on human health.  
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Background: The incidence of lung cancer is expected to increase due to increases in exposure 
to airborne pollutants and cigarette smoke. Moringa oleifera (MO), a medicinal plant found 
mainly in Asia and South Africa is used in the traditional treatment of various ailments 
including cancer. This study investigated the antiproliferative effect of MO leaf extract (MOE) 
in cancerous A549 lung cells. 
Methods: A crude aqueous leaf extract was prepared and the cells were treated with 166.7μg/ml 
MOE (IC50) for 24h and assayed for oxidative stress (TBARS and Glutathione assays), DNA 
fragmentation (comet assay) and caspase (3/7 and 9) activity. In addition, the expression of 
Nrf2, p53, Smac/DIABLO and PARP-1 was determined by Western blotting. The mRNA 
expression of Nrf2 and p53 was assessed using qPCR. 
Results: A significant increase in reactive oxygen species with a concomitant decrease in 
intracellular glutathione levels (p < 0.001) in MOE treated A549 cells was observed. MOE 
showed a significant reduction in Nrf2 protein expression (1.89-fold, p < 0.05) and mRNA 
expression (1.44-fold). A higher level of DNA fragmentation (p < 0.0001) was seen in the MOE 
treated cells. MOE’s pro-apoptotic action was confirmed by the significant increase in p53 
protein expression (1.02-fold, p < 0.05), p53 mRNA expression (1.59-fold), caspase-9 (1.28-
fold, p < 0.05), caspase-3/7 (1.52-fold) activities and an enhanced expression of 
Smac/DIABLO. MOE also caused the cleavage and activation of PARP-1 into 89 KDa and 24 
KDa fragments (p < 0.0001). 
Conclusion: MOE exerts antiproliferative effects in A549 lung cells by increasing oxidative 
stress, DNA fragmentation and inducing apoptosis. 
 
Keywords: Moringa oleifera, Drumstick tree, Lung cancer, Oxidative stress, Nrf2, Apoptosis 
 
Background 
Lung cancer is a leading cause of morbidity and mortality in many countries [1]. Inhalation of 
airborne pollutants, exposure to toxins present in grain dusts and fungal spores and cigarette 
smoking causes lung damage and increases the risk of carcinogenesis [2]. South Africa (SA) has 
the highest human immunodeficiency virus (HIV) infection burden globally and Bello et al. 
(2011) showed that surviving HIV positive individuals have a high risk of cancer such as lung 
cancer. Cancer deaths accounted for 63% in developing countries across the world [3]. Cancer is 
characterised by uncontrolled cell growth as cells proliferate and evade apoptosis [4]. Apoptosis 
is regulated by caspases through two pathways, viz., death receptor-mediated procaspase-





pathway (intrinsic pathway) [4, 5]. To maintain cellular homeostasis, these cells follow a 
process of growth, division and cell death. When this process is affected, it can result in the 
initiation of cancer. 
 
There are many regulators of apoptosis. The p53 tumor suppressor protein and transcription 
factor is up-regulated when DNA is damaged by causing G1 arrest and DNA repair; if the repair 
is unsuccessful then it signals for apoptosis and ultimately cell death [6, 7]. During apoptosis 
cellular proteins are proteolysed by caspases. These proteins also include poly (ADP ribose) 
polymerase-1 (PARP-1) [8]. 
 
Lung cancer still remains incurable and current drug therapies have many side-effects and 
alternate therapy is actively being sought [9]. If traditional medicine can provide an alternate 
source for treatment, the number of lung cancer deaths can be reduced. Some traditional 
medicines possess antiproliferative effects such as Sutherlandia frutescens, commonly referred 
to as cancer bush, is used by traditional healers in SA to treat cancer [10]. Moringa oleifera 
(MO), an indigenous tree to India, is found widely in SA [11]. It belongs to the family 
Moringaceae and is cultivated for medicinal and industrial purposes [12]. It is commonly 
referred to as the ‘tree of life’ or Drumstick tree [12, 13]. All parts of the MO plant possess 
medicinal properties, but the leaves have high nutritional value (high levels of vitamins C and 
A, potassium, proteins, calcium and iron) [14, 15]. In addition the leaves possess 
phytochemicals like carotenoids, alkaloids and flavonoids [11] and is rich in amino acids such 
as cystine, lysine, methionine and tryptophan [16]. MO is used in traditional treatment of 
diabetes mellitus, cardiovascular and liver disease. 
 
Phytochemical properties of MO play an important role in its mode of action against diseases 
[11]. It contains a rich source of rhamnose, glucosinolates and isothiocyanates. A study 
conducted by Manguro and Lemmen (2007) into the phenolics of MOE had characterised five 
flavonol glycosides using spectroscopic methods [17]. The anticancer property can be attributed 
to specific components of MOE such as 4-(α-L-rhamnopyranosyloxy) benzyl glucosinolate, 4-
(α-L-rhamnopyranosyloxy) benzyl isothiocyanate, benzyl isothiocyanate and niazimicin. The 
leaves contain quercetin-3-O-glucoside and kaempferol-3-O-glucoside which plays a role in 
antioxidant defence as it scavengers for free radicals thus reducing oxidative stress [12]. 
Thiocarbamates such as niazimicin are found in the leaves and can be used as a 
chemopreventive agent [18, 19]. Studies have suggested that the anticancer and 





MO leaf extracts have been shown to disrupt proliferation of cancer cells. In a study on Swiss 
mice, MO leaf extracts increased glutathione-S-transferase (GST) [12]. The MO leaf extracts 
induced apoptosis in KB carcinoma cells [22]. Sreelatha and Padma (2011) had shown that the 
extracts inhibited lipid peroxidation as it scavenged free radicals and reduced oxidative stress 
[22]. It also protected against oxidative DNA damage. To date there is no study assessing the 
effects of MO leaf extracts on lung carcinogenesis. The present study investigated the 
antiproliferative effects of a crude aqueous extract of MO leaves in A549 (human lung 
carcinoma) cells. It was hypothesised that MO leaf extracts induces cell death as a result of 




MO leaves were collected from the KwaZulu-Natal region (Durban, South Africa) and verified 
by the KwaZulu-Natal herbarium (Batch no. CT/1/2012, Genus no. 3128). A549 cells were 
purchased from Highveld Biologicals (Johannesburg, South Africa). Cell culture reagents were 
purchased from Whitehead Scientific (Johannesburg, South Africa). ECL-LumiGlo® 
chemiluminescent substrate kit was purchased from Gaithersburg (USA) and western blot 




A549 lung cells were cultured (37°C, 5% CO2) in 25cm3 culture flasks in complete culture 
media (CCM) [23] comprising of Eagle’s minimum essential medium supplemented with 10% 
foetal calf serum, 1% L-glutamine and 1% penicillin-streptomycin-fungizone until confluent 
[24]. Cell growth was monitored and CCM was changed as necessary. Confluent flasks were 
trypsinized using 1ml trypsin. Cell numbers were enumerated using trypan blue. 
  
Leaf extract 
The MO leaf extract (MOE) was prepared by crushing 10g of air-dried leaves in a pestle and 
mortar and the subsequent addition of 100ml de-ionised water [24, 25]. The resultant extract 
was boiled with continuous stirring for 20min, transferred to 50ml conical tubes and centrifuged 
[720xg, 10min, room temperature (RT)]. The upper aqueous layer (MOE) was removed, 
lyophilised and stored at 4°C. MOE stock solution was prepared by dissolving 1mg of MOE in 





Cell viability assay 
The cytotoxicity of MOE in A549 cells was determined using the Methyl thiazol tetrazolium 
(MTT) assay [26]. A549 cells (15,000 cells/well) were seeded into a 96-well microtitre plate. 
The cells were incubated with varying MOE dilutions (0, 1, 10, 50, 100, 150, 200, 250, 
500μg/ml) in six replicates (300μl/well) and incubated (37°C, 5% CO2) for 24h. A control of 
cells incubated with CCM only was used. A CCM/MTT salt solution (5mg/ml) was added 
(120μl/well) and the plate was incubated (37°C, 4h). Thereafter, supernatants were removed; 
dimethyl sulphoxide (DMSO) 100μl/well was added and incubated (1h). The optical density of 
the formazan product was measured at 570nm and reference wavelength of 690nm using a 
spectrophotometer (Bio Tek μQuant). The percentage cell viability was determined and a 
concentration-response curve was plotted using GraphPad Prism V5.0 software relative to the 
control. This experiment was repeated on two separate occasions before the concentration of 
half the maximum inhibition (IC50) was calculated. 
 
For subsequent assays, A549 cells at inoculation density of 20,000 cells per well were treated 
(24h) with the IC50 determined on viability assay. 
 
Lipid peroxidation - quantification of malondialdehyde (MDA) 
To investigate MOE generation of reactive oxygen species (ROS), Thiobarbituric acid assay 
(TBARS) was used. TBARS measures MDA which is the end product of lipid peroxidation and 
an indicator of oxidative stress [27]. Following treatment, cells lysed in 0.2% H3PO4 (100μl) by 
passing the cell solution through a 25 gauge needle at least 25 times from each sample was 
transferred to test tubes with the addition of 2% H3PO4 (200μl), 7% H3PO4 (400μl) and 
TBA/BHT solution (400μl). A positive control of MDA and a negative control of CCM were 
prepared. All samples were adjusted to pH 1.5 and heated (100°C, 15min). After cooling, 
butanol (1.5ml) was added to each test tube, vortexed and allowed to separate into distinct 
phases. The upper butanol phase (800μl) was transferred into eppendorfs and centrifuged 
(17,949xg, 6min, RT). 100μl from each sample was aliquoted into a 96-well microtitre plate in 
six replicates. The optical density was measured on a spectrophotometer at 532nm with 
reference wavelength of 600nm. The mean optical density for each sample was calculated and 
divided by the absorption coefficient (156 mM-1). The results were expressed in μM. 
 
Antioxidant potential - quantification of glutathione 
Glutathione-Glo™ Assay (Promega) was used according to manufacturer’s guidelines to 





was added in six replicates to the wells of an opaque polystyrene 96-well microtitre plate. GSH 
standards (0-50μM) were prepared from a 5mM stock diluted in de-ionised water. 50μl of each 
GSH standards and 50μl of the GSH-Glo™ Reagent 2X was added per well and incubated in 
the dark (30min, RT). Reconstituted Luciferin Detection Reagent (50μl) was added per well and 
incubated (15min, RT). The luminescence was measured on a Modulus™ microplate 
luminometer (Turner Biosystems, Sunnyvale, USA). The data was analysed and expressed as 
relative light units (RLU). 
 
DNA damage 
DNA damage was determined using the Comet assay [28]. Following treatment of cells (20,000 
cells/well) in a 6-well plate, supernatants were removed and cells were trypsinized. Three slides 
per sample were prepared as the first layer of 1% low melting point agarose (LMPA, 37°C), 
second layer of 25μl of cells (20,000) from the samples with 175μl of 0.5% LMPA (37°C) and 
third layer of 0.5% LMPA (37°C) covered the slides. After solidification, the slides were then 
submerged in cold lysing solution [2.5M NaCl, 100mM EDTA, 1% Triton X-100, 10mM Tris 
(pH 10), 10% DMSO] and incubated (4°C, 1h). Following incubation the slides were placed in 
electrophoresis buffer [300mM NaOH, 1mM Na2EDTA (pH 13)] for 20min and thereafter 
subjected to electrophoresis (25V, 35min, RT) using Bio-Rad compact power supply. The slides 
were then washed 3 times with neutralisation buffer [0.4M Tris (pH 7.4)] for 5min each. The 
slides were stained overnight (4°C) with 40μl ethidium bromide (EtBr) and viewed with a 
fluorescent microscope (Olympus IXSI inverted microscope with 510-560nm excitation and 
590nm emission filters). Images of 50 cells and comets were captured per treatment and the 
comet tail lengths were measured using Soft imaging system (Life Science - ©Olympus Soft 
Imaging Solutions v5) and expressed in μm. 
 
Caspase-3/7 and 9 activities 
Caspase-Glo® 3/7 and Caspase-Glo® 9 Assays (Promega) were used to assess apoptosis. For 
each assay the same procedure was followed: A549 cells were seeded into an opaque 
polystyrene 96-well microtitre plate in six replicates. Following treatment, the Caspase-Glo® 3/7 
and Caspase-Glo® 9 reagents were prepared according to manufacturer’s guidelines. 100μl of 
the reagent was added per well and incubated in the dark (30min, RT). Following incubation, 
the luminescence was measured on a Modulus™ microplate luminometer. The data was 







Western Blots were performed to determine the expression of Nrf2, p53, Smac/DIABLO and 
PARP-1. Briefly, total protein was isolated using Cytobuster™ reagent supplemented with 
protease inhibitor (Roche, cat. no. 05892791001) and phosphatase inhibitor (Roche, cat. no. 
04906837001). The bicinchoninic acid assay (Sigma, Germany) was used to quantify the 
protein and was standardised to 2.042mg/ml [29]. The samples were prepared in Laemmli 
buffer [30], boiled (100°C, 5min) and electrophoresed (150V, 1h) in 7.5% sodium dodecyl 
sulfate polyacrylamide gels using a Bio-Rad compact power supply. The separated proteins 
were electro-transferred to nitrocellulose membrane using the Trans-Blot® Turbo Transfer 
system (Bio-Rad) (20V, 45min). The membranes were blocked (1h) using 3% BSA in Tris-
buffered saline containing 0.5% Tween20 (TTBS - NaCl, KCL, Tris, Tween 20, dH2O, pH 7.4). 
Thereafter, the membranes were immune-probed with primary antibody [Nrf2 (ab89443), p53 
(ab26), PARP-1 (ab110915), 1:1,000; Smac/DIABLO (ab68352), 1:200] at 4°C overnight. The 
membranes were then washed 4x with TTBS (10min each) and incubated with the secondary 
antibody (ab97046; 1:2,000) at RT for 1h. The membranes were finally washed 4x with TTBS 
(10min each). To correct for loading error and to normalise the expression of the proteins, β-
actin was assessed (ab8226; 1:5,000). Horse radish peroxidase (HRP) chemiluminescence 
detector and enhancer solution was used for the antigen-antibody complex and the signal was 
detected with the Alliance 2.7 image documentation system (UViTech). The expression of the 
proteins were analysed with UViBand Advanced Image Analysis software v12.14 (UViTech). 
The data was expressed as relative band density (RBD) and fold change. 
 
Quantification of mRNA 
To determine p53 and Nrf2 mRNA expression, RNA was first isolated from control and MOE 
treatment by adding 500μl Tri reagent (Am9738) as per manufacturer’s guidelines. Thereafter, 
RNA was quantified (Nanodrop 2000) and standardised to 100ng/μl. RNA was reverse 
transcribed by reverse transcriptase into copy DNA (cDNA) using the RT2 First Strand Kit 
(SABiosciences, C-03) as per manufacturer’s instructions. Briefly, a 20μl reaction was prepared 
by adding 10μl genomic DNA elimination mixture (Total RNA, 5x gDNA elimination buffer, 
H2O) to 10μl of RT cocktail (5x RT buffer 3, primer and external control mix, RT enzyme mix, 
H2O). The reaction was then subjected to 42°C (15min) and 95°C (5min) (GeneAmp® PCR 
System 9700, Applied Biosystems) to obtain cDNA. Quantitative PCR (qPCR) was used to 
determine mRNA expression using RT2 SYBR® Green qPCR Master Mix (SABiosciences). A 
25μl reaction consisting of 12.5μl IQ™ SYBR® green supermix (cat. no. 170-8880), 8.5μl 





Table 1) were used. The mRNA expression was compared and normalised to a housekeeping 
gene, GAPDH. 
 
Table 1 Primer sequences used in qPCR assay 
Primer sequence 
 Sense Primer Anti-sense Primer 
Nrf2 5′AGTGGATCTGCCAACTACTC 3′ 5′CATCTACAAACGGGAATGTCTG 3′ 
p53 5′CCACCATCCACTACAACTACAT3′ 5′CAAACACGGACAGGACCC3′ 
GAPDH 5′TCCACCACCCTGTTGCTGTA3′ 5′ACCACAGTCCATGCCATCAC3′ 
 
The reaction was subjected to an initial denaturation (95°C, 10min). It was followed by 40 
cycles of denaturation (95°C, 15s), annealing (Nrf2: 57°C, 40s; p53: 56°C, 40s) and extension 
(72°C, 30s) (Chromo 4 Real-Time PCR detector, Biorad). The data was analysed using MJ 
opticon monitor analysis software V3.1, Biorad. The mRNA expression was determined using 
the Livak method and expressed as fold changes [31]. 
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism v5.0 software (GraphPad Software 
Inc., La Jolla, USA). The results were expressed as means with standard deviation (SD). The 
concentration-response-inhibition equation was used to determine IC50 for MTT assay. The 
statistical significances were determined by unpaired t-test and a 95% confidence interval. The 
data were considered statistically significant with a value of p < 0.05. 
 
Results 
Cell viability assay 
The MTT assay measures cell viability based on the generation of reducing equivalents in 













Table 2 Viability of A549 cells treated with MOE for 24h 
Concentration (μg/ml) Mean OD ± SD Cell Viability (%) 
0 (Control) 1.469 ± 0.008 100 
1 1.177 ± 0.058 80.123 
10 1.120 ± 0.132 76.242 
50 1.001 ± 0.118 68.108 
100 1.201 ± 0.082 81.756 
150 1.170 ± 0.110 79.646 
200 0.966 ± 0.158 65.725 
250 0.922 ± 0.177 62.730 
500 0.984 ± 0.350 66.950 
OD: optical density, SD: standard deviation. 
 
Using GraphPad prism, an IC50 value of 166.7μg/ml was calculated. This concentration of MOE 
was used in all subsequent assays. 
 
Assessment of oxidative stress 
Reactive oxygen species (ROS) induce oxidative stress. Lipid peroxidation, caused by ROS, 
was assayed by quantifying MDA presented in Figure 1A. 
 
 
Figure 1 Oxidative stress induced by MOE on A549 cells.  
An increase in MDA levels (lipid peroxidation) (A) and decreased intracellular GSH levels (B) 
in MOE treated cells (**p < 0.001). 
 
There was a significant increase in MDA levels in MOE treatment as compared to the untreated 





decreased in the MOE treatment compared to the control [Figure 1B (2.507 x 106 ± 0.081 x 106 
RLU vs 3.751 x 106 ± 0.110 x 106 RLU, p < 0.001): Additional file 1]. 
 
DNA damage 
The comet assay assessed DNA damage and the comet tail lengths were measured in MOE 
treated and untreated A549 cells (Figure 2). 
 
 
Figure 2 Comet assay images of control and MOE treatments for 24h.  
DNA damage was higher in cells exposed to MOE (B) then control cells (A) (100x, ***p < 
0.0001). 
 
There was a significant increase in comet tail length in MOE treatment compared to the control 
(18.52 ± 4.90μm vs 5.15 ± 1.18μm, p < 0.0001). 
 
Assessment of caspase-3/7 and 9 activities 
Intracellular activity of caspases-3/7 and caspase-9 was measured. Table 3 presents the 
apoptotic induction in A549 cells. 
 
Table 3 Apoptotic markers of A549 cells following treatment for 24h 
 Mean ± SD (RLU x 105) Fold change p-value 
Control MOE 
Caspase-3/7 2.097 ± 0.489 3.196 ± 0.261 1.52 0.107 
Caspase-9 12.630 ± 0.020 16.160 ± 0.702 1.28 < 0.05* 







There was an increase (non-significant) in caspase-3/7 activity and a significant increase in 
caspase-9 activity in MOE treatment compared to the control (Table 3). 
 
Western blotting 
To determine the effect of MOE on protein expression we assessed the levels of Nrf2, p53, 
Smac/DIABLO and PARP-1 using western blot (Figure 3). 
 
 
Figure 3 MOE regulating protein expression in A549 cells.  
Differential expression of Nrf2, p53, Smac/DIABLO, PARP-89 KDa and 24 KDa fragment in 
A549 cells after treatment with MOE for 24h. 
 
MOE induced a significant 1.89-fold decrease in Nrf2 expression [Figure 3 (0.069 ± 0.007 RBD 
vs control: 0.129 ± 0.022 RBD, p < 0.05)]; a 1.02-fold increase in p53 expression [Figure 3 
(0.567 ± 0.002 RBD vs control: 0.558 ± 0.002 RBD, p < 0.05)] and a 1.06-fold increase in 
Smac/DIABLO expression [Figure 3 (1.509 ± 0.055 RBD vs control: 1.425 ± 0.007 RBD, p = 
0.162)]. During apoptosis, PARP-1 is proteolysed by caspases to an 89 KDa and 24 KDa 
fragment. There was a significant 1.27-fold decrease in the expression of PARP 89 KDa 
fragment in the MOE treatment compared to the control [Figure 3 (0.234 ± 0.005 RBD vs 0.297 
± 0.005 RBD, p < 0.0001)] and a 1.46-fold increase in the level of PARP 24 KDa fragment 






Quantification of mRNA 
The mRNA expression of Nrf2 and p53 in A549 cells was determined using qPCR relative to 
the control (Figure 4). 
 
 
Figure 4 The effect of MOE on mRNA expression.  
MOE regulated the Nrf2 and p53 mRNA expression in A549 cells after treatment for 24h (**p < 
0.001). 
 
The Nrf2 mRNA expression was decreased 1.44 ± 0.03-fold (p < 0.001) in MOE treatment 
(Figure 4). A 1.59 ± 0.41-fold (p = 0.168) increase in p53 mRNA expression was observed in 
MOE treated cells. 
 
Discussion 
MO, a widely consumed traditional plant, is used to treat various ailments such as cancer [13]. 
Cancer is listed as the fourth leading cause of death in SA [3], with lung cancer expected to 
increase. This is a first study to show a possible biochemical mechanism of action of MOE on 
cancerous A549 cells. 
 
Reactive oxygen species are known to induce many diseases [32]. These oxidants damage 
membrane phospholipids and results in lipid peroxidation [2, 27]. This study showed that MOE 
significantly increased lipid peroxidation as measured by elevated levels of MDA. This lipid 
peroxidation compromises cell membranes and their function. In addition, the mitochondrial 





increased electron leak from the respiratory chain. These oxidants also react with proteins and 
DNA in the cell [33]. 
 
Hydrogen peroxide (H2O2) oxidises cysteine in GSH to produce glutathione disulphide (GSSG), 
thereby decreasing the antioxidant capacity of GSH. GSH levels were significantly decreased in 
MOE-treated A549 cells with a corresponding significant increase in lipid peroxidation (Figure 
1). 
 
The mRNA plays a pivotal role in protein synthesis as it is used as a template and thus 
translated into protein [34]. The transcription factor nuclear factor-erythroid 2 p45-related factor 
2 (Nrf2) is important in antioxidant defence as it protects the cell from oxidative stress. Nrf2 
dissociates from Kelch-like epichlorohydrin-associated protein 1 (Keap1) and translocates to the 
nucleus and binds to the antioxidant-response elements in promoter regions of antioxidant genes 
thus increasing transcription [35, 36]. Nrf2 regulates the synthesis of GSH and MOE reduced 
mRNA expression by 1.44-fold (Figure 4) [34]. This resulted in a significant decrease in Nrf2 
protein expression in A549 cells, (Figure 3) which leads to decreased transcription of important 
antioxidant genes and increased oxidative damage [37]. The suppression of Nrf2 expression 
may explain the antiproliferative effect of MOE in this cell line. A consequence is that the 
endogenous antioxidant GSH is not replenished adequately and will result in increased oxidants 
and ultimately to cell death. 
 
The increase in oxidative stress is genotoxic to the cell. H2O2 can react with metal ions such as 
iron and produce highly reactive hydroxyl radicals that target DNA [22]. ROS-mediated DNA 
damage can be a therapeutic target in cancer cells as it signals nucleases to cause DNA strand 
breaks. The MOE induced significant DNA strand breaks and fragmentation in the alveolar 
epithelial cells (Figure 2). Again this finding shows that MOE possess pro-apoptotic and 
antiproliferative properties. 
 
To further confirm the pro-apoptotic action of MOE, we investigated its effect on p53 mRNA 
and protein expression. MOE increased p53 mRNA expression (Figure 4) with a significant 
increase in the expression of p53 protein in A549 treated cells (Figure 3). It is known that an 
increase in oxidative stress and DNA damage results in apoptosis [38, 39]. DNA damage up-
regulates signals for repair and apoptosis. The increased expression of p53 correlates well with 
the increased DNA damage by MOE. This signals for apoptosis via Bax activation, a pro-





mitochondria into the cytoplasm. Cytochrome c, together with Apaf-1 and ATP forms an 
apoptosome resulting in pro-caspase-9 cleavage and activation of caspase-9. MOE significantly 
increased (1.28-fold) caspase-9 activity, which in turn activates the executioner caspases-3/7 
(1.52-fold increase) (Table 3). Caspase-3/7 activity can be inhibited by inhibitor of apoptosis 
(IAP) proteins [40, 41]. The protein, Smac/DIABLO is concurrently released from the 
mitochondria with cytochrome c and inhibits IAP proteins thus ensuring execution of apoptosis. 
MOE afforded a slight increase on Smac/DIABLO expression (1.06-fold) [Figure 3 (1.509 ± 
0.055 RBD vs control: 1.425 ± 0.007 RBD, p = 0.162)] that could contribute to the apoptotic 
pathway. 
 
In addition PARP-1 cleavage was investigated. During apoptosis, caspases are activated 
resulting in the cleavage of PARP-1 [6]. PARP-1, a nuclear enzyme, is proteolysed to an 89 
KDa C-terminal catalytic fragment and a 24 KDa N-terminal DNA-binding domain fragment 
[42]. PARP-1 (important in DNA base excision repair) maintains the integrity of the genome 
[43]. MOE increased caspase-3/7 activity in A549 cells which resulted in cleavage of PARP-1 
into 2 fragments [44]. There was a significant (1.46-fold) increase in the expression of the 24 
KDa fragment (Figure 3) in MOE treated cells. This increased cleavage of the smaller PARP-1 
fragment correlates well with the increased DNA damage by MOE (p < 0.0001). 
 
The phytoconstituents of MOE were shown to possess antiproliferative effects on various cell 
lines [20]. The leaves contain glucosinolates, isothiocyanates, niazimicin, niaziminin and 
quercetin which attributes to the anticancer effect [11, 20, 21]. In addition the leaves also 
contain other thiocarbamate, carbamates and nitrile glycosides [20]. 
 
A recent study showed the significance of MO phytochemicals in prostate cancer therapy [21]. 
Niazimicin and 4-(4’-O-acetyl-α-L-rhamnopyranosyloxy) benzyl isothiocyanate were identified 
as natural anticancer agents and compared favourably with the recommended chemotherapeutic 
drug, Estramustine. These phytochemicals enhanced the activity of cellular prostatic acid 
phosphatase and possessed less toxicity, thus showing potential as a potent and safe natural 
agent in prostate cancer therapy and drug design [21]. Similarly these active compounds in 
MOE can act as anticancer agents in lung cancer by inducing cellular apoptosis and subsequent 
cell death. 
 
An in vivo study on the anticancer activity of MOE on B16 F10 melanoma tumors in mice, 





The anticancer activity was attributed to the phytochemicals quercetin, niazimicin and 
niaziminin. The therapeutic and nutritional use of MOE is safe at doses below 2g/kg-bw [45]. 
Similarly the antiproliferative effect of MOE observed in the A549 cancerous cells may be due 




The MO leaves possess antiproliferative properties as evidenced by an increase in oxidative 
stress leading to apoptosis of lung cancer cells. The results from the study provide a 
biochemical mechanism underlying the usage of MOE as a therapeutic agent in lung cancer 
therapy. It shows a promising complementary and alternative treatment for lung cancer. 
Furthermore, phytochemical analysis (Appendix 3) and the effect of MOE on other cancerous 
cell lines need to be assessed. 
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Oesophageal cancer (OC) is commonly diagnosed in South Africa (SA) with high incidences 
occurring in SA’s black population. Moringa oleifera (MO), a multipurpose tree, is used 
traditionally for its nutritional and medicinal properties. It has been used for the treatment of a 
variety of ailments including cancer.  
Aim: We investigated the antiproliferative effect of MO crude aqueous leaf extract (MOE) in a 
cancerous oesophageal cell line (SNO).  
Methods: SNO cells and normal peripheral blood mononuclear cells (PBMCs) were exposed to 
a range of MOE dilutions to evaluate cytotoxicity (MTT assay). Oxidative stress and DNA 
fragmentation was determined using TBARS, GSH and comet assay respectively. Apoptosis 
was then determined by measuring phosphatidylserine (PS) externalisation (flow cytometry), 
caspase-3/7, -9 activity and ATP levels (luminometry). Protein expression of Nrf2, p53, 
Smac/DIABLO and PARP-1 was determined by western blotting, whilst Nrf2 and catalase 
mRNA levels were assessed by qPCR.  
Results: MOE was only cytotoxic in SNO cancer cells (IC50: 389.2µg/ml, 24h) causing a 
significant increase in lipid peroxidation, DNA fragmentation and significantly decreasing GSH 
levels. Both catalase and Nrf2 protein and mRNA levels were significantly decreased. The 
induction of apoptosis was confirmed by the significant increase in PS externalisation, caspase-
9, caspase-3/7 (p = 0.22) activities and significant decrease in ATP levels. Further, MOE 
significantly increased the expression of p53, Smac/DIABLO and cleavage of PARP-1, 
resulting in an increase in the 24kDa fragment.   
Conclusion: MOE possesses antiproliferative effects in SNO cancer cells by increasing 
oxidative stress, DNA fragmentation and inducing apoptosis.  
 
Keywords: Apoptosis, DNA fragmentation, Oxidative stress, Nrf2, SNO cancer cells   
 
Introduction 
Cancer is one of the leading causes of global mortality with oesophageal cancer (OC) being 
ranked the sixth most common cause of death1. Cancer cells do not undergo apoptosis as they 
continue to divide and proliferate2. The apoptotic machinery maintains homeostasis and is 
composed of the intrinsic and extrinsic pathways regulated by caspases3. Disruptions to this 
machinery is the hallmark of cancer pathogenesis3. In developing countries such as South Africa 
(SA), the burden of cancer continues to increase4. Oesophageal cancer is most common in black 
men in SA and the increased prevalence may be due to presence of mycotoxins such as 





be attributed to diet and lifestyle such as excessive consumption of home-made beer (brewed 
from fungal contaminated maize) and maize products. Family history, tobacco smoking, dietary 
deficiencies and chronic alcohol consumption contributes to the aetiology of OC1, 7.  
 
The incidence of OC in black South Africans are suggested to be associated with high intake of 
linoleic acid via maize consumption6. Sammon and Alderson., 1998 showed that linoleic acid 
increases prostaglandin E2 (PGE2) levels which inhibits gastric acid secretion and affects pyloric 
and oesophageal sphincters8. This causes hypochlorhydric duodenogastro-oesophageal reflux 
altering pH levels rendering inhibition of protease activity and function and non-breakdown of 
growth factors. This may contribute to carcinogenesis as cell signal transduction increases 
causing cell proliferation and tumour progression. 
 
Studies on high OC risk populations have shown that individuals from the rural areas in  
Transkei and KwaZulu-Natal (SA) have poorer diets and lack basic health care9. They often rely 
on traditional plants which are readily available as food sources and treatment of various 
ailments including cancer. Moringa oleifera (MO; Family: Moringaceae) commonly known as 
the Drumstick tree is indigenous to India and also found throughout SA10-12.  Almost all parts of 
the tree possess nutritional and medicinal properties however the leaves are suggested to be the 
highest containing vitamins, minerals, iron, essential amino acids and proteins. Several studies 
have shown that MO leaves possess antioxidant, anticancer properties and used in treatment of 
diabetes mellitus and liver diseases10, 12, 13.  Phytochemical analysis showed the presence of 
bioactive compounds such as flavonoids, glucosinolates, isothiocyanates, niazimicin and gallic 
acid which possess anticancer effects10-12, 14. Current cancer therapies are expensive and often 
lead to drug resistance; therefore alternative, cost effective, traditional based treatment is being 
investigated. This study investigated the antiproliferative effect of MO crude aqueous leaf 
extract in cancerous oesophageal SNO cells.          
 
Materials and Methods 
Materials 
Moringa oleifera leaves were collected from the KwaZulu-Natal region (Durban, SA) and 
verified by the herbarium (Batch no. CT/1/2012, Genus no. 3128). SNO cells were purchased 
from Highveld Biologicals (Johannesburg, SA). Cell culture reagents were purchased from 
Whitehead Scientific (Johannesburg, SA). ECL-LumiGlo® chemiluminescent substrate kit was 
purchased from Gaithersburg (USA) and western blot reagents were purchased from Bio-Rad 





 Leaf extract 
The MO leaf extract (MOE) was prepared by crushing 10g of air-dried leaves in a pestle and 
mortar with subsequent addition of 100ml de-ionised water15-17. The resultant extract was boiled 
with continuous stirring (20min), transferred to 50ml conical tubes and centrifuged [720xg, 
10min, room temperature (RT)]. The upper aqueous layer (MOE) was removed, lyophilised and 
stored (4°C). MOE stock solution was prepared (1mg MOE in 1ml CCM) and filter sterilised 
[0.22μM filter (Millipore)]. 
 
Peripheral blood mononuclear cell extraction 
Whole blood was obtained from a healthy male donor on three independent occasions and the 
peripheral blood mononuclear cells (PBMCs) were isolated from heparinised whole blood by 
differential centrifugation [Ethical approval from the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (Reference number: BE057/15) and informed consent was 
obtained]. Briefly, 5ml of whole blood was layered onto equivolume Histopaque 1077 (Sigma, 
Germany) in 15ml conical tubes and centrifuged (400xg, 30min, RT). The buffy coat layer 
containing PBMCs were aspirated into sterile 15ml conical tubes and washed twice in 0.1M 
phosphate buffered saline (PBS) (400xg, 10min). Cell numbers were then enumerated using 
trypan blue. 
 
Cell culture and exposure protocol   
SNO cells were cultured in 25cm3 culture flasks (37ºC, 5% CO2) in complete culture media 
(CCM) comprising of Eagle’s minimum essential medium supplemented with 10% foetal calf 
serum, 1% L-glutamine and 1% penicillin-streptomycin-fungizone18. Isolated PBMCs were 
cultured at 37ºC with 5% CO2 in Roswell park memorial institute (RPMI) medium 1640 
supplemented with 10% foetal calf serum, 1% L-glutamine and 1% penicillin-streptomycin-
fungizone18. SNO cells were grown to 90% confluency and treated with MOE; 20,000 cells per 
sample in all luminometric and colorimetric assays, 1,000,000 cells for flow cytometric analysis 
and 2,500,000 cells for western blot and qPCR analysis were used. Three experiments were 
conducted per assay.  
 
Cell viability assay   
SNO and PBMCs cell viability was determined using the 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-
diphenyl-2H-tetrazolium bromide (MTT) assay19. Cells (20,000cells/well) were seeded into a 
96-well microtitre plate. The cells were incubated with varying MOE dilutions (0.1-10mg/ml) in 





with CCM only. A CCM/MTT salt solution (5mg/ml) was added (120µl/well) and the plate was 
incubated (37ºC, 4h). Thereafter, supernatants were removed; dimethyl sulphoxide (DMSO) 
100µl/well was added and incubated (1h). The optical density of the formazan product was 
measured (570/690nm) using a spectrophotometer (Bio Tek μQuant). The results were 
expressed as percentage cell viability relative to the control. This experiment was repeated on 
three separate occasions before the concentration of half the maximum inhibition (IC50) of MOE 
for the cells (SNO and PBMCs) were determined. Due to minimal toxicity observed in PBMCs, 
all other experiments were conducted on SNO cells to determine the mechanism of cell death. 
 
Lipid peroxidation - quantification of malondialdehyde (MDA) 
Thiobarbituric acid (TBARS) assay was used to assess reactive oxygen species (ROS) by 
measuring MDA, end product of lipid peroxidation20. Following treatment, cells were lysed in 
0.2% H3PO4 (100μl) by passing the cell solution through a 25 gauge needle at least 25x and was 
transferred to test tubes with addition of 2% H3PO4 (200μl), 7% H3PO4 (400μl) and TBA/BHT 
solution (400μl). A positive control of MDA and a negative control of CCM were prepared. All 
samples were adjusted to pH 1.5 and heated (100°C, 15min). After cooling, butanol (1.5ml) was 
added, vortexed and allowed to separate into distinct phases. The upper butanol phase (800μl) 
was transferred into eppendorfs and centrifuged (17,949xg, 6min, RT). 100μl from each sample 
was added to a 96-well microtitre plate in six replicates. The optical density was measured on a 
spectrophotometer (532/600nm). The mean optical density was calculated, divided by the 
absorption coefficient (156mM-1) and expressed in μM. 
 
Glutathione (GSH) quantification 
Glutathione-Glo™ Assay (Promega) was used according to manufacturer’s guidelines to 
quantify reduced GSH levels. 50μl from each sample (MOE treated and untreated control) was 
added in six replicates to the wells of an opaque polystyrene 96-well microtitre plate. GSH 
standards (0-50μM) were prepared from a 5mM stock diluted in de-ionised water. 50μl of each 
GSH standards and 50μl of the GSH-Glo™ Reagent 2X was added per well and incubated in 
the dark (30min, RT). Reconstituted Luciferin Detection Reagent (50μl) was added per well and 
incubated (15min, RT). The luminescence was measured on a Modulus™ microplate 
luminometer (Turner Biosystems, Sunnyvale, USA). The data was analysed and expressed in 









DNA damage was determined using the Comet assay21. Three slides per sample were prepared 
as the first layer of 1% low melting point agarose (LMPA, 37°C), second layer of 25μl of cells 
(20,000) from the samples with 175μl of 0.5% LMPA (37°C) and third layer of 0.5% LMPA 
(37°C) covered the slides. After solidification, the slides were then submerged in cold lysing 
solution [2.5M NaCl, 100mM EDTA, 1% Triton X-100, 10mM Tris (pH 10), 10% DMSO] and 
incubated (4°C, 1h). Following incubation the slides were placed in electrophoresis buffer 
[300mM NaOH, 1mM Na2EDTA (pH 13)] for 20min and thereafter subjected to 
electrophoresis (25V, 35min, RT) using Bio-Rad compact power supply. The slides were 
washed 3x with neutralisation buffer [0.4M Tris (pH 7.4)] (5min each). The slides were stained 
overnight (4°C) [40μl ethidium bromide (EtBr)] and viewed with a fluorescent microscope 
(Olympus IXSI inverted microscope with 510-560nm excitation and 590nm emission filters). 
Images of 50 cells and comets were captured per treatment and the comet tail lengths were 
measured using Soft imaging system (Life Science - ©Olympus Soft Imaging Solutions v5) and 
expressed in μm. 
 
Assessment of phosphatidylserine (PS) externalisation  
The Annexin-V-Fluos assay (Roche) was used to detect PS externalisation, an early marker of 
apoptosis. 100µl of each sample (1,000,000cells/tube) were transferred to polystyrene flow 
cytometry tubes, stained with 100µl annexin-V-Fluos labelling solution and incubated in the 
dark (15min, RT). 400µl of Annexin-V Binding buffer (1x) was added and the labelled cells 
were detected by fluorescence-activated cell sorting (FACS) Calibur flow cytometer (BD 
Biosciences, SA). The cells were gated to exclude cellular debris using FlowJo v7.1 software 
(Tree Star Inc., Ashland, USA). Approximately 50,000 events were obtained and the data was 
analysed using CellQuest PRO v4.02 software (BD Biosciences, SA). The data was expressed 
as relative fold change. 
 
ATP quantification   
The CellTitre-Glo® assay (Promega) was used to quantify ATP levels. SNO cells 
(20,000cells/well) were seeded into an opaque polystyrene 96-well microtitre plate in six 
replicates. Following treatment, the CellTiter-Glo® Reagent 2X was prepared according to 
manufacturer’s guidelines and 100µl of the reagent was added per well. The plate was then 
incubated in the dark (30min, RT). Following incubation, the plate was read on the ModulusTM 






Caspase-9 and 3/7 activities                                                                                            
Caspase-Glo® 9 and Caspase-Glo® 3/7 Assays (Promega) were used to assess apoptosis. For 
each assay the same procedure was followed: SNO cells were seeded into an opaque 
polystyrene 96-well microtitre plate in six replicates. Following treatment, the Caspase-Glo® 9 
and Caspase-Glo® 3/7 reagents were prepared according to manufacturer’s guidelines. 100µl of 
the reagent was added per well and incubated in the dark (30min, RT). Following incubation, 
the luminescence was measured on a ModulusTM microplate luminometer. The data was 
expressed as RLU and fold change.  
 
Western blotting                                                                                              
Western Blotting assessed Nrf2, p53, Smac/DIABLO and PARP-1 protein expression. Briefly, 
total protein was isolated using CytobusterTM reagent supplemented with protease inhibitor 
(Roche, cat. no. 05892791001) and phosphatase inhibitor (Roche, cat. no. 04906837001). The 
bicinchoninic acid assay (Sigma, Germany) was used for protein quantification and was 
standardised to 1mg/ml22. The samples were prepared in Laemmli buffer23, boiled (100ºC, 
5min) and electrophoresed (150V, 1h) in 7.5% sodium dodecyl sulfate polyacrylamide gels 
using Bio-Rad compact power supply. The separated proteins were electro-transferred to 
nitrocellulose membrane using the Trans-Blot® Turbo Transfer system (Bio-Rad) (20V, 45min). 
The membranes were blocked (1h) using 3% bovine serum albumin (BSA) in Tris-buffered 
saline containing 0.5% Tween20 (TTBS - NaCl, KCL, Tris, Tween 20, dH2O, pH 7.4). 
Thereafter, the membranes were immune-probed with primary antibody [Nrf2 (ab89443), p53 
(ab26), PARP-1 (ab110915), 1:1000; Smac/DIABLO (ab68352), 1:200] at 4ºC overnight. The 
membranes were washed 4x (TTBS, 10min each) and incubated with secondary antibody 
(ab97046; 1:2,000) at RT (1h). The membranes were washed 4x (TTBS, 10min each). To 
correct for loading error and normalise protein expression, β-actin was assessed (ab8226; 
1:2,000). Horseradish peroxidase chemiluminescence detector and enhancer solution was used 
and the signal was detected with Alliance 2.7 image documentation system (UViTech). Protein 
expression were analysed with UViBand Advanced Image Analysis software (UViTech, 
v12.14). The data expressed as relative band density (RBD) and fold change.  
 
Quantification of mRNA  
To determine Nrf2 and catalase mRNA levels in SNO cells, RNA was first isolated from the 
control and MOE treatment by adding 500μl Tri reagent (Life technologies Am9738) as per 
manufacturer’s guidelines. Thereafter, RNA was quantified (Nanodrop 2000) and standardised 





using the iScriptTM cDNA synthesis kit (Bio-Rad, SA, cat. no. 1708891) as per manufacturer’s 
instructions. Briefly, a 20μl reaction was prepared by adding 4μl 5x iScript reaction mix, 1μl 
iScript reverse transcriptase, 12μl nuclease free water, 3μl RNA template. The reaction was then 
subjected to 25°C (5min), 42°C (30min), 85°C (5min) and a final hold at 4°C [CFX96 Real 
Time thermal cycler (Bio-Rad, SA)] to obtain cDNA. 
 
Quantitative PCR (qPCR) was used to determine mRNA levels using iQ Superscript reagent 
(Bio-Rad, SA). A 25μl reaction consisting of 12.5μl IQ™ SYBR® green supermix (Bio-Rad, 
SA, cat. no. 170-8880), 8.5μl nuclease free water, 2μl cDNA, and 1μl sense and anti-sense 
primer (10µM, Inqaba Biotec, SA, Table 1) were used. The mRNA levels was compared and 
normalised to a housekeeping gene, GAPDH. The reaction was subjected to an initial 
denaturation (95°C, 8min). It was followed by 40 cycles of denaturation (95°C, 15s), annealing 
(Nrf2, catalase: 58°C, 40s) and extension (72°C, 30s) [CFX96 Real Time thermal cycler (Bio-
Rad, SA)]. The data was analysed using CFX ManagerTM software V3.0 (Bio-Rad, SA). The 
mRNA levels were determined using the Livak method and expressed as fold changes24.  
 
Table 1: Primer sequences used in qPCR assay 
Primer sequence 
 Sense Primer Anti-sense Primer 
Nrf2 5′ AGTGGATCTGCCAACTACTC 3′ 5′ CATCTACAAACGGGAATGTCTG 3′ 
Catalase 5′ TAAGACTGACCAGGGCATC 3′ 5′ CAAACCTTGGTGAGATCGAA 3′ 
GAPDH 5′ TCCACCACCCTGTTGCTGTA 3′ 5′ ACCACAGTCCATGCCATCAC 3′ 
 
Statistical analysis                                                                                                             
Statistical analyses were performed using GraphPad Prism v5.0 software (GraphPad Software 
Inc., La Jolla, USA). The results were expressed as means with standard error of the mean 
(SEM). The statistical significances were determined by student t-test with 95% confidence 
interval. The data were considered statistically significant with a value of p < 0.05. 
 
Results 
Cell viability assay 
MOE induced a dose-dependent decline in SNO cell viability and an IC50 value of 389.2µg/ml 
was obtained and used in all subsequent assays (Figure 1). MOE showed a proliferative effect in 







Figure 1: % SNO and normal PBMCs cell viability after exposure to MOE for 24h 
 
Oxidative stress 
The TBARS assay was used to measure MDA levels (a measure of lipid peroxidation). A 
significant increase in MDA levels was seen in the MOE treatment (0.09 ± 0.01µM vs control: 
0.07 ± 0.00µM; *p < 0.05) (Figure 2A). 
 
Figure 2: Oxidative stress in SNO cells after exposure to MOE for 24h (*p < 0.05) 
 
Further the antioxidant, GSH, was significantly decreased as compared to the untreated control 










The comet assay showed MOE was genotoxic as observed by the significantly increased DNA 
fragmentation in SNO cells compared to the untreated control (Figure 3; 46.09 ± 0.77 vs 21.44 
± 0.36; ***p < 0.0001). 
  
 
Figure 3: Comet assay images of control (A) and MOE treated (B) SNO cells for 24h (***p < 
0.0001, 100x) 
 
Assessment of apoptosis  
The effect of MOE on apoptotic markers i.e. PS externalisation, caspase activity and ATP levels 
was determined (Table 2). 
 
Table 2: Apoptotic markers in SNO cells after treatment with MOE for 24h 
 Mean ± SEM  
 Control MOE p-value 
PS externalisation (relative 
fold change) 
1 2.52  <0.0001*** 
ATP (x105  RLU)    69.82 ± 1.43       50.29 ± 0.53 <0.0001*** 
Caspase-9 (x105  RLU)    29.19 ± 0.57       32.72 ± 0.80 <0.05* 
Caspase-3/7 (x105 RLU)      2.31 ± 0.03         2.51 ± 0.11 0.22 
***p < 0.0001, *p < 0.05: significantly different compared to the control, SEM: standard error 
of the mean, RLU: relative light units, PS: phosphatidylserine 
 
A significant increase in PS externalisation was seen in the MOE treated cells. In addition, an 





significant 1.39-fold decrease in cellular ATP levels in the MOE treatment compared to the 
untreated control.    
    
Western Blotting 
The protein levels of Nrf2, p53, Smac/DIABLO and PARP-1 was assessed using western 
blotting (Figure 4).  
 
Figure 4: Protein levels (A) and the relative fold change (B) in SNO cells after exposure to 
MOE for 24h (**p < 0.001, *p < 0.05) 
 
Exposure to MOE caused a significant 1.49-fold decrease in Nrf2 levels (0.18 ± 0.02 RBD vs 
control: 0.27 ± 0.01 RBD, **p < 0.001) (Figure 4). There was a 1.24-fold increase in p53 levels 
compared to the control (0.16 ± 0.00 RBD vs 0.13 ± 0.01, *p < 0.05). A 1.82-fold increase in 
Smac/DIABLO levels in the MOE treated SNO cells was seen (0.45 ± 0.03 RBD vs control: 
0.25 ± 0.02 RBD, **p < 0.001) (Figure 4). Also, there was a 1.37-fold increase in the levels of 
cleaved PARP-1 (24kDa fragment) (0.17 ± 0.01 vs control: 0.13 ± 0.00, **p < 0.001) (Figure 
4).   
 
Quantification of mRNA  








Figure 5: mRNA expression in SNO cells after exposure to MOE for 24h (***p < 0.0001, **p < 
0.001) 
 
A significant 4.76 ± 0.03-fold (***p < 0.0001) decrease in Nrf2 mRNA expression was seen in 
the MOE treated SNO cells (Figure 5). In addition, catalase expression was also decreased by 
1.64 ± 0.09-fold (**p < 0.001). 
 
Discussion 
The balance between cell proliferation and apoptosis is critical for cellular homeostasis25. Often 
in disease states, there is aberration in apoptosis potentially leading to carcinogenesis. 
Oesophageal cancer is one of the leading causes of cancer mortality1 in SA. MOE is used 
traditionally throughout SA for the treatment of various ailments including cancer10. MOE 
caused a dose-dependent decline in SNO cell viability with no cytotoxicity in normal healthy 
PBMCs (Figure 1). MOE is rich in nutrients with high levels of amino acids and proteins26, 27. 
MOE contains glutamine which can be utilised as an energy source by lymphocytes28. The 
increased rate of the normal PBMCs metabolism/viability may be due to the abundant supply of 
glutamine. We then investigated the antiproliferative effect of MO crude aqueous leaf extract in 
SNO oesophageal cancer cells. 
 
Reactive oxygen species (ROS) are countered in cells by the production of antioxidants, 
however ROS overproduction results in oxidative stress29. A chronic increase in oxidative stress 
has been implicated in damage to proteins, lipids and DNA. Free radicals react with 





significantly increased ROS levels evidenced by lipid peroxidation in SNO cells (Figure 2A). 
Cancer cells have higher metabolic activity30 therefore exposure to compounds such as MOE 
which contain polyphenols may increase levels of ROS. Polyphenols present in MOE such as 
gallic acid possess pro-oxidant properties and induced apoptosis in cancer cell lines31. 
Chlorogenic acid, also a polyphenol present in MOE caused ROS induced apoptosis in K562 
leukaemia cells and human oral squamous cell carcinoma32. MOE also affected the antioxidant 
response in SNO cells by significantly decreasing GSH levels (Figure 2B). The transcription 
factor, nuclear factor-erythroid 2 p45-related factor 2 (Nrf2), regulates cellular antioxidant 
enzymes by binding to the antioxidant response element (ARE) in the promoter region and 
increases the transcription of antioxidant and cytoprotective genes33. GSH homeostasis is 
maintained via Nrf2 transcription. MOE significantly decreased both Nrf2 mRNA (Figure 5) 
and protein (Figure 4) expression in SNO cancer cells. A consequence of decreased Nrf2 levels 
will result in inadequately replenished GSH and antioxidant response. Catalase mRNA levels 
were also significantly reduced (Figure 5). An imbalance between ROS and antioxidants in 
SNO cells resulted in oxidative stress. In addition, highly reactive hydroxyl radicals target DNA 
and induce damage34. A significant increase in DNA fragmentation was observed in MOE 
treated cells (Figure 3).  
 
The mitochondrion is a source of ROS production35. High levels of ROS and oxidative DNA 
damage signals for p53 induction of apoptosis via the mitochondria (intrinsic apoptotic 
pathway). MOE significantly increased p53 protein levels (Figure 4) which signals for 
activation of a pro-apoptotic molecule Bax36. Bax activation leads to mitochondrial release of 
cytochrome c (cyt c) into the cytoplasm, forms an apoptosome with ATP and Apaf-1, causing 
the cleavage and activation of caspase-937. MOE increased caspase-9 and caspase-3/7 activity 
(Table 2) suggesting intrinsic pathway of apoptosis. Studies have shown that MOE possess 
anticancer properties and induced apoptosis in various cancer cell lines12, 13. MOE’s 
phytochemical composition showed that it abundantly contains glucosinolates, flavonoids, and 
phenolic acids38. In addition, it also contains niazimicin, 4-(α-L-rhamnopyranosyloxy) benzyl 
glucosinolate, 4-(α-L-rhamnopyranosyloxy) benzyl isothiocyanate39, quercetin and kaempferol 
contributing to the antiproliferative effect we observed in SNO cells40. The bioactive compound, 
gallic acid, have induced apoptosis in 3T3-L1 pre-adipocytes by caspase-9 and -3/7 activation31. 
Gallic acid subsequently caused the cleavage of poly (ADP-ribose) polymerase (PARP-1). 
 
PARP-1 is a DNA repair-associated enzyme that maintains genome integrity41. When apoptosis 





24kDa fragment inhibiting its repair mechanism and cell survival function41, 42. MOE caused 
cleavage of PARP-1 with a significant increase in the 24kDa fragment (Figure 4). This again 
shows MOE’s apoptosis inducing effect in SNO cells. The 24kDa fragment (DNA binding 
domain) irreversibly binds to DNA stand breaks, preventing repair, ultimately committing to 
cell death.  
 
Furthermore Smac/DIABLO is concurrently released from the mitochondria which prevents 
inhibitor of apoptosis proteins (IAP’s) from halting the apoptotic machinery. Smac/DIABLO 
proteins levels were significantly increased (Figure 4) thus allowing the execution of apoptosis. 
Chlorogenic acid induced ROS production with subsequent release of cyt c and Smac/DIABLO 
from the mitochondria in K562 leukaemia cells leading to apoptosis32. Similarly in SNO cells, 
the significant increase in expression may be attributed to chlorogenic acid that is present in the 
crude extract. In addition, MOE increased PS externalisation (2.52-fold) from the inner leaflet to 
the outer plasma membrane43.    
 
Charoensin, 2014 showed that MOE possess antiproliferative properties in HepG2, MCF-7, 
fibroblast cells and induced quinone reductase activity, an anticarcinogenic phase II enzyme40. 
In addition, MOE decreased NFkB signalling and synergistically acted with cisplatin to cause 
cytotoxicity in pancreatic cancer cells44. Studies suggest that the intake of MOE is safe below 
2g/kg-bw45. Further analysis conducted on the SNO cells treated with MOE over longer time 
period, 48h and 72h, also showed a dose-dependent decline in cell viability (data not shown) 
(Appendix 4). Therefore MOE’s antiproliferative effect in SNO cells can be attributed to its 
phytochemical composition.      
 
MOE exerts an antiproliferative effect in SNO cells by inducing the intrinsic apoptotic pathway. 
The study shows a possible use of MOE in the treatment of oesophageal cancer. However 
phytochemical analysis (Appendix 3) to identify bioactive compounds will ascertain the 
antiproliferative effect.  
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Gold nanoparticles (AuNP’s) facilitate cancer cell recognition and can be manufactured by 
green synthesis using nutrient rich medicinal plants such as Moringa oleifera (MO). Targeting 
dysregulated oncogenes and tumor suppressor genes is crucial for cancer therapeutics. 
Aim: We investigated the antiproliferative effects of AuNP synthesised from MO aqueous leaf 
extracts (MLAuNP) in A549 lung and SNO oesophageal cancer cells.  
Methods: A one-pot green synthesis technique was used to synthesise MLAuNP. A549, SNO 
cancer cells and normal peripheral blood mononuclear cells (PBMCs) were exposed to MLAuNP 
and CAuNP to evaluate cytotoxicity (MTT assay); apoptosis was measured by phosphatidylserine 
(PS) externalisation, mitochondrial depolarisation (ΔΨm) (flow cytometry), caspase-3/7, -9 
activity and ATP levels (luminometry). The mRNA expression of c-myc, p53, Skp2, Fbw7α and 
caspase-9 splice variants was determined using qPCR, whilst relative protein expression of c-
myc, p53, SRp30a, Bax, Bcl-2, Smac/DIABLO, Hsp70 and PARP-1 were determined by 
western blotting. 
Results: MLAuNP and CAuNP were not cytotoxic to PBMCs, whilst its pro-apoptotic properties 
were confirmed in A549 and SNO cells. MLAuNP significantly increased caspase activity in SNO 
cells while MLAuNP significantly increased PS externalisation, ΔΨm, caspase-9, caspase-3/7 
activities and decreased ATP levels in A549 cells. Also, p53 mRNA and protein levels, SRp30a 
(p=0.428), Bax, Smac/DIABLO and PARP-1 24kDa fragment levels were significantly 
increased. Conversely, MLAuNP significantly decreased Bcl-2, Hsp70, Skp2, Fbw7α, c-myc 
mRNA and protein levels and activated alternate splicing with caspase-9a splice variant being 
significantly increased. 
Conclusion: MLAuNP possesses antiproliferative properties and induced apoptosis in A549 cells 
by activating alternate splicing of caspase-9. 
 
Introduction 
Cancer is the second leading cause of mortality worldwide following cardiovascular disease 
with approximately 8.2 million cancer deaths (21.7%  of noncommunicable diseases) and 14.1 
million new diagnoses [Globocan, 2012; Mendis et al., 2014]. Cancer mortality is projected to 
increase to 12.6 million by year 2030. Lung cancer alone accounts for 1.59 million deaths and is 
the leading cause of cancer mortality [Globocan, 2012]. Despite major advancements in cancer 
therapies, it remains incurable and quality of life after diagnosis is reduced [Cheng et al., 2005]. 
Bello et al. (2011) suggested South Africans are at higher risk of developing lung cancer due to 






Cancer cells are able to proliferate through activation of oncogenes (e.g. c-myc) and inactivation 
of tumor suppressor genes (e.g. p53) [Bonomi et al., 2013]. Oncogenes and dysregulation of 
tumor suppressor genes encourage tumor progression. Apoptosis maintains homeostasis and any 
disruption to this process leads to cancer pathogenesis. c-Myc, a transcription factor, regulates 
gene expression for cell growth and apoptosis [Chen et al., 2013], whilst Skp2 (S-phase kinase-
associated protein 2) and Fbw7 (F-box and WD repeat domain-containing 7) mediate the 
posttranslational regulation of c-myc. Skp2 also acts as an oncogene and is overexpressed in 
human cancers [Chen et al., 2013].   
 
Cancer cells metabolic activity are increased enabling them to rapidly divide [Eblen, 2012]. 
Chemotherapeutic agents are non-specific as they target these rapidly dividing cells at the 
expense of normal healthy cells [Eblen, 2012]. Differential expression of genes and proteins are 
seen in chemotherapy resistance. The cellular proteome is a key regulator in chemotherapy. 
Fundamental processes such as gene expression, mRNA transcription and translation into 
protein as well as modification and degradation of proteins influence the cellular proteome. In 
particular, alternate splicing of pre-mRNA also affects the cellular proteome as it determines 
which variant of the gene is translated, resulting in proteins with differing functional efficacy. 
For example, the splice variant of caspase-9 has shown that expression of caspase-9b inhibits 
apoptosis and is implicated in chemotherapy resistance [Shultz et al., 2011]. On the other hand, 
caspase-9a expression induces apoptosis and thus regulation of inclusion/exclusion of exon 3, 
4, 5, 6 cassette is a determinant of cell fate. This process is often manipulated by cancer cells to 
ensure their survival [Eblen, 2012]. 
 
Emerging cancer therapies such as nanoparticles (NP’s) are now being developed to specifically 
target cancer cells [Zhang et al., 2003]. Nanoparticles have characteristic properties of being 
very small (1-100nm) [Kumar et al., 2011] and are able to interact with biomolecules both on 
the cell surface and intracellularly [Cai et al., 2008]. Nanoparticles are useful in anticancer drug 
delivery systems however, their exact mechanism of action still remains to be elucidated [Kang 
et al., 2010]. Among the many nanoparticles being developed, studies show that gold 
nanoparticles (AuNP’s) are stable and can easily enter a cell, and are useful in the treatment of 
rheumatoid arthritis, possess anticancer and antimicrobial properties and have good 
biocompatibility [Kumar et al., 2011; Siddiqi et al., 2012; Tedesco et al., 2010]. Gold 
nanoparticles also have therapeutic potential as an anti-HIV agent [Kumar et al., 2011]. The 
advantage of AuNP’s is that they are biologically inert and non-toxic [Lim et al., 2011; Parveen 





commercially in demand. Nanoparticle properties and applications are due to their size and 
shape [Xie et al., 2007b; Xie et al., 2009].  Nanoparticles are synthesised chemically or via the 
use of medicinal plants [Prasad and Elumalai, 2011]. In addition, NP’s can be synthesised using 
biological extracts such as green algae and bovine serum albumin [Xie et al., 2007a; Xie et al., 
2007c]. The use of plant extracts to synthesise nanoparticles is recently discovered [Prasad and 
Elumalai, 2011] and this green chemistry is cost effective and advantageous in large scale 
production, especially in third world countries [Salamanca-Buentello et al., 2005].  
   
Moringa oleifera (MO) belongs to the family Moringaceae, commonly known as Drumstick tree 
[Fahey, 2005; Goyal et al., 2007], is indigenous to India and is also found widely in South 
Africa (SA). Almost all parts of the tree possess medicinal properties however the leaves 
contain high nutritional source of vitamins, calcium, iron, potassium, proteins and possess 
antioxidant, anticancer and hepatoprotective properties [Prasad and Elumalai, 2011; Sreelatha et 
al., 2011]. Due to SA’s socio-economic, cultural background and minimal support of basic 
healthcare in rural areas, MO has been widely used for the treatment and management of 
malnutrition, diabetes mellitus, cardiovascular and liver diseases amongst several others [Erasto 
et al., 2005; Goyal et al., 2007]. The leaf extract contain bioactive compounds which aid in its 
anticancer activity. These compounds include niazimicin, gallic acid, rhamnose, glucosinolates 
and isothiocyanates [Fahey, 2005; Goyal et al., 2007; Mishra et al., 2011]. Recently, AuNP’s of 
MO flower petals were prepared and showed activity in A549 lung cancer cells [Anand et al., 
2014]. Our study now is on the leaf extract which was used in an environmentally friendly 
synthesis of AuNP’s (MLAuNP). We investigated the antiproliferative and apoptosis inducing 
effects of a novel MLAuNP in cancerous A549 lung cells. It was hypothesized that MLAuNP has an 
antiproliferative effect by inducing apoptosis in A549 cells as a result of MLAuNP selectively 
targeting oncogenes and tumor suppressor genes.  
 
Materials & Methods 
Materials 
Moringa oleifera leaves were collected from the KwaZulu-Natal region (Durban, SA) and 
verified by the KwaZulu-Natal (SA) herbarium (Batch no. CT/1/2012, Genus no. 3128). Gold 
(III) chloride trihydrate (HAuCl4.3H2O) was purchased from Sigma-Aldrich, SA. A549 cells 
were purchased from Highveld Biologicals (Johannesburg, SA). Cell culture reagents were 
purchased from Whitehead Scientific (Johannesburg, SA). ECL-LumiGlo® chemiluminescent 





blot reagents were purchased from Bio-Rad (USA). All other reagents were purchased from 
Merck (SA). 
 
Synthesis of MLAuNP 
A one-pot green synthesis technique was used to synthesise MLAuNP [Anand et al., 2014; Li et 
al., 2015]. The synthesis and characterization were conducted at Durban University of 
Technology (Durban, SA). The MO leaf extract was prepared as per Tiloke et al. (2013) [Tiloke 
et al., 2013]. The resultant extract (5ml) was added to 1mM aqueous gold chloride solution 
(100ml) and allowed to react at room temperature (RT) for the reduction of Au3+ ions to Au. 
MLAuNP were then characterized and particle size was determined using UV spectrometry and 
transmission electron microscopy respectively. In addition, further characterisation of the 
hydrodynamic size and size distribution of the MLAuNP was determined using dynamic light 
scattering (DLS) and Image J. The Zeta potential of MLAuNP was also assessed.  
 
Synthesis of Trisodium citrate gold nanoparticles (CAuNP) – chemical synthesis method  
The synthesis and characterisation were conducted at Durban University of Technology 
(Durban, SA). A volume of 100ml Au (III) (1.4mM) was used with the addition of 2ml of 
0.34M trisodium citrate. This was allowed to stir continuously for the production of CAuNP.  
 
Peripheral blood mononuclear cell extraction 
Whole blood was obtained from a healthy male donor and the peripheral blood mononuclear 
cells (PBMCs) were isolated from heparinized whole blood by differential centrifugation 
[Ethical approval from the University of KwaZulu-Natal Biomedical Research Ethics 
Committee (Reference number: BE057/15) and informed consent was obtained]. Briefly, 5ml of 
whole blood was layered onto equivolume Histopaque 1077 (Sigma, Germany) in 15ml conical 
tubes and centrifuged (400xg, 30min, RT). The buffy coat layer containing PBMCs were 
aspirated into sterile 15ml conical tubes and washed twice in 0.1M phosphate buffered saline 
(PBS) (400xg, 10min). Cell numbers were then enumerated using trypan blue.  
 
Cell culture and exposure protocol   
A549 and SNO cells were cultured in 25cm3 culture flasks in complete culture media (CCM) 
comprising of Eagle’s minimum essential medium (EMEM) supplemented with 10% foetal calf 
serum, 1% L-glutamine and 1% penicillin-streptomycin-fungizone [Wilson and Walker, 2005]. 
Cell growth was monitored and cultures were maintained at 37ºC with 5% CO2.  A549 and SNO 





were cultured at 37ºC with 5% CO2 in Roswell park memorial institute (RPMI) medium 1640 
supplemented with 10% foetal calf serum, 1% L-glutamine and 1% penicillin-streptomycin-
fungizone [Wilson and Walker, 2005]. Cell density at 20,000 was used per sample in all 
luminometric and colorimetric assays. A549 cell density at 1,000,000 cells was used for flow 
cytometric analysis and 2,500,000 cells for western blot and qPCR analysis. 
 
Cell viability assay   
The viability of A549, SNO cells and PBMCs after exposure to CAuNP and MLAuNP was 
determined using the 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide 
(MTT) assay [Mossman, 1983]. Cells were seeded into a 96-well microtitre plate (20,000 
cells/well). The cells were incubated with varying CAuNP concentrations (1.9 - 475µg/ml) and  
MLAuNP concentrations (1.575 - 393.83µg/ml) in six replicates (300µl/well) and incubated 
(37ºC, 5% CO2) for 24h. Control cells were incubated with CCM only. A CCM/MTT salt 
solution (5mg/ml) was added (120µl/well) and the plate was incubated (37ºC, 4h). Thereafter, 
supernatants were removed; dimethyl sulphoxide (DMSO) 100µl/well was added and incubated 
(1h). The optical density of the formazan product was measured (570/690nm) using a 
spectrophotometer (Bio-Tek μQuant, USA). The results were expressed as percentage cell 
viability relative to the control. This experiment was repeated on two separate occasions before 
the IC50 of CAuNP and MLAuNP for the cells (A549, SNO and PBMCs) were determined. Due to 
minimal toxicity observed in PBMCs, all other experiments were conducted on A549 and SNO 
cells to determine the mechanism of cell death. 
 
ATP quantification   
The CellTitre-Glo® assay (Promega) was used to quantify ATP in samples which is an 
indication of metabolically active cells. A549 and SNO cells (20,000 cells/well) were seeded 
into an opaque polystyrene 96-well microtitre plate in six replicates. Following treatment, the 
CellTiter-Glo® Reagent 2X was prepared according to manufacturer’s guidelines and 100µl of 
the reagent was added per well. The plate was then incubated in the dark (30min, RT). 
Following incubation, the plate was read on the Modulus™ microplate luminometer. The 
luminescent signal was measured which is proportional to the amount of ATP present and the 
data was expressed as RLU and fold change.  
 
Caspase-3/7 and 9 activities                                                                                 
Caspase-Glo® 3/7 and Caspase-Glo® 9 Assays (Promega) were used to assess apoptosis. For 





seeded into an opaque polystyrene 96-well microtitre plate in six replicates. Following 
treatment, the Caspase-Glo® 3/7 and Caspase-Glo® 9 reagents were prepared according to 
manufacturer’s guidelines. A volume of 100µl of the reagent was added per well and incubated 
in the dark (30min, RT). Following incubation, the luminescence was measured on a Modulus™ 
microplate luminometer. The data was expressed as RLU and fold change.  
 
Assessment of phosphatidylserine externalisation  
The Annexin-V-Fluos assay (Roche) was used to detect phosphatidylserine (PS) externalisation. 
PS is externalised in both apoptotic and necrotic cells and is therefore differentiated by addition 
of propidium iodide (PI). PI only stains DNA of necrotic cells. A volume of 100µl of each 
sample (1,000,000 cells/tube) were transferred to polystyrene flow cytometry tubes, stained 
with 100µl annexin-V-Fluos labelling solution and incubated in the dark (15min, RT). A 
volume of 400µl of Annexin-V Binding buffer (1x) was added to the samples and the labelled 
cells were detected by fluorescence-activated cell sorting (FACS) Calibur flow cytometer (BD 
Biosciences, SA). The cells were gated to exclude cellular debris using FlowJo v7.1 software 
(Tree Star Inc., Ashland, USA). Approximately 50,000 events were obtained and the data was 
analyzed using CellQuest PRO v4.02 software (BD Biosciences, SA).  The data was expressed 
as a percentage of apoptotic cells. 
 
Mitochondrial membrane potential  
The JC-1 Mitoscreen assay was used to assess mitochondrial membrane potential according to 
manufacturers’ guidelines. A volume of 100µl of each sample (1,000,000 cells/tube) was 
transferred to polystyrene flow cytometry tubes with the addition of 150µl JC-1 dye and 
incubated (37ºC, 5% CO2, 10min). The cells were washed twice with JC-1 wash buffer (1x). 
Between washes cells were centrifuged (400xg, 5min). Cells were re-suspended in 200µl flow 
cytometry sheath fluid and labelled cells were detected on FACS Calibur flow cytometer. The 
cells were gated to exclude cellular debris using FlowJo v7.1 software. 50,000 events were 
obtained and the data was analyzed using CellQuest PRO v4.02 software. The results were 
expressed as a percentage of cells containing depolarised mitochondria.  
 
Western blotting                                                                                              
Western Blots were performed to determine the protein levels of c-myc, p53, SRp30a, Bax, Bcl-
2, Smac/DIABLO, Hsp70 and PARP-1. Briefly, total protein was isolated using Cytobuster™ 
reagent supplemented with protease inhibitor (Roche, SA, cat. no. 05892791001) and 





(Sigma, Germany) was used to quantify the protein and was standardized to 1.066mg/ml 
[Bainor et al., 2011]. The samples were prepared in Laemmli buffer [Yang and Ma, 2009], 
boiled (100ºC, 5min) and electrophoresed (150V, 1h) in 7.5% sodium dodecyl sulfate 
polyacrylamide gels using a Bio-Rad compact power supply. The separated proteins were 
electro-transferred to nitrocellulose membrane using the Trans-Blot® Turbo Transfer system 
(Bio-Rad, SA) (20V, 45min). The membranes were blocked (1h) using 3% bovine serum 
albumin (BSA) in Tris-buffered saline (TTBS - NaCl, KCL, Tris, Tween 20, dH2O, pH 7.4). 
Thereafter, the membranes were immune-probed with primary antibody [p53 (ab26), PARP-1 
(ab110915), 1:1,500; c-myc (Cell Signaling #9402), SRp30a (PA5-30220), Bax (ab5714), Bcl-2 
(Cell Signaling #3869), Hsp70 (BD610607), 1:1,000; and Smac/DIABLO (ab68352), 1:200] at 
4ºC overnight. The membranes were then washed 4x with TTBS (10min each) and incubated 
with secondary antibody [mouse (ab97046), rabbit (sc-2004), 1:2,000] at RT for 1h. The 
membranes were finally washed 4x with TTBS (10min each). To correct for loading error and to 
normalise the expression of the proteins, β-actin was assessed (ab8226; 1:2,000). Horseradish 
peroxidase chemiluminescence detector and enhancer solution was used for the antigen-
antibody complex and the signal was detected with the Alliance 2.7 image documentation 
system (UViTech). The expression of the proteins was analyzed with UViBand Advanced 
Image Analysis software (UViTech, v12.14). The data was expressed as relative band density 
(RBD) and fold change.  
 
Quantification of mRNA  
To determine c-myc, p53, skp2 and Fbw7α mRNA levels in A549 cells, RNA was first isolated 
from the control and MLAuNP treatment by adding 500μl Tri reagent (Life technologies Am9738) 
as per manufacturer’s guidelines. Thereafter, RNA was quantified (Nanodrop 2000) and 
standardized to 600ng/μl. RNA was reverse transcribed by reverse transcriptase into copy DNA 
(cDNA) using the iScriptTM cDNA synthesis kit (Bio-Rad, SA, cat. no. 1708891) as per 
manufacturer’s instructions. Briefly, a 20μl reaction was prepared by adding 4μl 5x iScript 
reaction mix, 1μl iScript reverse transcriptase, 12μl nuclease free water, 3μl RNA template. The 
reaction was then subjected to 25°C (5min), 42°C (30min), 85°C (5min) and a final hold at 4°C 
[CFX96 Real Time thermal cycler (Bio-Rad, SA)] to obtain cDNA. 
 
Quantitative PCR (qPCR) was used to determine mRNA levels using iQ Superscript reagent 
(Bio-Rad, SA). A 25μl reaction consisting of 12.5μl IQ™ SYBR® green supermix (Bio-Rad, 
SA, cat. no. 170-8880), 8.5μl nuclease free water, 2μl cDNA, and 1μl sense and anti-sense 





normalized to a housekeeping gene, GAPDH. The reaction was subjected to an initial 
denaturation (95°C, 8 min). It was followed by 40 cycles of denaturation (95°C, 15s), annealing 
(c-myc, p53, Skp2, Fbw7α: 56°C, 40s) and extension (72°C, 30s) [CFX96 Real Time thermal 
cycler (Bio-Rad, SA)]. The data was analyzed using CFX ManagerTM software V3.0 (Bio-Rad, 
SA). The mRNA levels was determined using the Livak method and expressed as fold changes 
[Livak and Schmittgen, 2001]. 
 
Table 1 Primer sequences used in qPCR assay 
Primer sequences 
 Sense Primer Anti-sense Primer 
   
c-myc 5’-AGCGACTCTGAGGAGGAACAAG-3’ 5’-GTGGCACCTCTTGAGGACCA-3’ 
p53 5’-CCACCATCCACTACAACTACAT-3’ 5’-CAAACACGGACAGGACCC-3’ 
Skp2 5’-TGGGAATCTTTTCCTGTCTG-3’ 5’-GAACACTGAGACAGTATGCC-3’ 
Fbw7α 5’-AGTAGTATTGTGGACCTGCCCGTT-3’ 5’-GACCTCAGAACCATGGTCCAACTT-3’ 
GAPDH 5’-TCCACCACCCTGTTGCTGTA-3’ 5’-ACCACAGTCCATGCCATCAC-3’ 
 
Alternate splicing of caspase-9 
To determine the expression of caspase-9 splice variants, caspase-9 sense primer  
(5’-GCTCTTCCTTTGTTCATCTCC-3’) and anti-sense primer  
(5’ CATCTGGCTCGGGGTTACTGC 3’) (10mM, Inqaba Biotec, SA) were used [Massiello 
and Chalfant, 2006; Shultz et al., 2011; Shultz et al., 2010]. The reaction was subjected to an 
initial denaturation (94°C, 8 min). It was followed by 35 cycles (20% of the reverse 
transcriptase reaction was amplified) of denaturation (94°C, 30s), annealing (caspase-9: 58°C, 
30s) and extension (72°C, 1min) [CFX96 Real Time thermal cycler (Bio-Rad, SA)]. The qPCR 
product was examined on 1.5% agarose gel using Alliance 2.7 image documentation system 
(UViTech). Densitometric analysis [UViBand Advanced Image Analysis software (UViTech, 
v12.14)] was conducted to assess caspase-9a and caspase-9b splice variant. The data was 







Statistical analysis                                                                                                            
Statistical analyses were performed using GraphPad Prism v5.0 software (GraphPad Software 
Inc., La Jolla, USA). The results were expressed as means with standard error of the mean 
(SEM). The comparisons and statistical significances were determined by unpaired t-test and a 




Phytochemical analysis of Moringa oliefera aqueous leaf extract 
 
 
Figure 1 Chemical composition of Moringa oleifera aqueous leaf extract by GC-MS 
analysis 
 
Moringa oleifera aqueous leaf extract showed eleven peaks in the GC-MS chromatogram 
(Figure 1). The compounds were separated according to their retention time on fused silica 
capillary column. The total ion chromatogram (TIC) indicates the presence of various organic 
compounds with significant abundant peaks at retention time 7.55, 8.75, 10.87, 12.22, 14.26, 





142.0, 58.0, 60.0, 310.0, 338.0, 352.0, 279.0, 366.0 and 380.0 respectively. These compounds 
mainly comprised of hydrocarbons and phenolic compounds. Pyran-4-one (7.55), 2-
Furancarboxaldehyde (8.75), Docosane (19.36), Tetracosane (21.21), Pentacosane (22.34), 
Heptacosane (23.72) identified as major chemical constituents followed by Octacosane (25.44) 
[Al-Owaisi et al., 2014].  
 
Synthesis of MLAuNP 
The molar calculation of the crude leaf extract cannot be determined. We synthesised the 
MLAuNP’s on the basis of weight percent ratios of leaf extract and gold chloride. In the present 
study - 5g of leaf in 100ml water and 0.0393g of gold chloride in 100ml of water, making the 
final W% ratio is 5:0.039% [Shankar et al., 2004] 
 
A colour change to red-brown (Figure 2.1) within a few seconds of mixing the leaf extract with 
the HAuCl4 solution supported the formation of MLAuNP’s. This was attributed to the excitation 
of surface plasmon vibrations in gold nanoparticles. The observation validated the reduction of 
Au3+ ions to Au by the plant components. The Surface Plasmon Resonance (SPR) is visible as a 
broad band at λmax 542nm (Figure 2.1), consistent with literature [Stuchinskaya et al., 2011]. 
The UV-visible absorption spectra of both aqueous leaf extract (Figure 2.2 A) as well as gold 







Figure 2 The UV-visible absorption spectra of 1) AuNP’s biosynthesised by aqueous leaf 
extract of Moringa oleifera Insert 2.1: The colour change when MLAuNP’s were formed (A) 
Aqueous leaf extract (B) Gold chloride solution (C) Gold nanoparticles 2) (A) Aqueous leaf 
extract (B) Gold chloride solution 3) Stability of MLAuNP’s at 544nm UV-visible absorption 
spectra analysis after six months 
 
The obtained MLAuNP’s dispersion was stable for over six months at room temperature. The 
peak at 544nm in UV-visible absorption spectra (Figure 2.3) is attributed to the surface plasmon 
resonance of stable AuNPs. Also, the plasmon band has been sharp and symmetric, which 
indicates that the solution does not contain much of aggregated particles after six months. 
 
The transmission electron microscopy (TEM) micrographs and size distribution of the MLAuNP’s 
indicated that most of the particles are spherical or near spherically shaped, however, some 
polyhedral particles are also present. It was also observed that the MLAuNP’s were highly poly-







Figure 3 Representative TEM micrograph of MLAuNP’s biosynthesised by aqueous leaf 
extract of Moringa oleifera 




Figure 4 The hydrodynamic size of MLAuNP showed a maximum intensity at 26.44nm as 







Figure 5 The size distribution of MLAuNP (Image J) 
 
The size distribution of MLAuNP was determined by DLS. The average hydrodynamic size was 
26.44nm (Figure 4 and Figure 5) which were similar to Melia azedarach’s leaf extract 
[Sukirtha et al., 2012]. The MLAuNP size obtained from TEM and DLS was different. This can 







Figure 6 Stability of MLAuNP’s at -25.3mV in zeta potential analysis 
 
Many reports have proposed that surface active molecules can stabilise the nanoparticles and 
that the reaction of the metal ions is possibly facilitated by reducing sugars and or plant based 
organic molecules. However, a stable dispersion of particles was evident from the zeta potential 
of -25.3mV (Figure 6); a zeta potential higher than 30mV or lesser than -30mV is indicative of 
a stable system [Kotakadi et al., 2014]. 
 
Cell viability assay 
MLAuNP and trisodium citrate AuNPs (CAuNP) (synthesised by conventional chemical methods) 
cytotoxicity in A549 lung cancer cells, SNO oesophageal cancer cells and normal healthy 
PBMCs was then determined using the MTT assay. CAuNP and MLAuNP treatment for 24h caused 
a dose-dependent decline in A549 and SNO cell viability. CAuNP IC50 value was determined as 
121.4µg/ml (A549) and 410.4µg/ml (SNO) (Figure 7A). An IC50 value of 98.46µg/ml (A549) 
and 92.01µg/ml (SNO) was calculated for MLAuNP (Figure 7B). Furthermore, CAuNP and MLAuNP 
showed no cytotoxicity in normal healthy PBMCs (Figure 7A and B respectively) and an IC50 







Figure 7 Percentage A549, SNO and PBMCs cell viability after exposure to CAuNP and 
MLAuNP for 24h     
The MTT assay was used to determine A549, SNO and PBMCs cell viability. A dose-
dependent decline in A549 and SNO cell viability was observed whereas no cytotoxicity was 
observed in PBMCs. 
 
Assessment of apoptosis induction 
The percentage of apoptosis induced in both A549 and SNO cells by MLAuNP is presented in 






Table 2 ATP and caspase activity in A549 and SNO cells following treatment with MLAuNP 
for 24h 
***p < 0.0001, **p < 0.001, *p < 0.05 *: Significantly different compared to control, SEM: 
standard error of the mean, RLU: relative light unit 
 
Table 3 Phosphatidylserine externalisation and mitochondrial depolarisation in A549 cells 
following treatment with MLAuNP for 24h 
***p < 0.0001, **p < 0.001, *p < 0.05 *: Significantly different compared to control, SEM: 
standard error of the mean, PS: Phosphatidylserine, ΔΨm: Mitochondrial depolarisation 
 
An early marker of apoptosis is PS externalisation which was significantly increased in A549 
cells (3.88-fold, Table 3). MLAuNP altered mitochondrial function by significantly increasing 
ΔΨm (1.43-fold) and simultaneously decreasing ATP levels (1.20-fold) (Table 2 and 3) in A549 
cells. The ATP levels in SNO cells were decreased by CAuNP and MLAuNP (1.01-fold and 5.05-
fold respectively) (Table 2). Also, executioner caspase-3/7 (1.34-fold) and initiator caspase-9 
(1.14-fold) activities were increased by MLAuNP treatment in A549 cells as compared to the 
control (Table 2). In addition, CAuNP and MLAuNP increased executioner caspase-3/7 significantly 
in SNO cells (2-fold and 2.5-fold respectively) (Table 2). Also initiator caspase-9 increased 
after exposure to CAuNP and MLAuNP in the cancerous SNO cells (1.01-fold and 1.12-fold 
respectively) (Table 2). 
 
 A549 cells (mean ± SEM)  SNO cells (mean ± SEM) 
 Control MLAuNP Control CAuNP MLAuNP 
      
ATP  
(x105 RLU) 
20.47 ± 0.13   17.12 ± 0.33***  33.36 ± 0.44  32.96 ± 0.86    6.61 ± 0.05*** 
Caspase-3/7 
(x105 RLU) 
 0.54  ± 0.02   0.73  ± 0.03**   0.02 ± 0.00    0.04 ± 0.00*  0.05 ± 0.00** 
Caspase-9  
(x105 RLU) 
  4.34 ± 0.00  4.94 ± 0.09*   1.96 ± 0.00  1.97 ± 0.04    2.20 ± 0.00* 
 A549 cells (mean ± SEM)  
 Control MLAuNP 
PS extenalisation (%)  1.03  ± 0.07     3.99 ± 0.04*** 





Western Blotting  
The protein levels of c-myc, p53, SRp30a, Bax, Bcl-2, Smac/DIABLO, Hsp70 and PARP-1 
were assessed using western blot (Figure 8). 
 
 
Figure 8 The effect of MLAuNP on protein levels in A549 cells 
Western blot analysis of protein levels (A) and the relative fold change (B) in A549 lung cancer 
cells after exposure to MLAuNP (***p < 0.0001, **p < 0.001, *p < 0.05). Apoptotic proteins were 
significantly increased with a simultaneous decrease in anti-apoptotic proteins. Protein bands 
were normalised against β-actin.   
 
Oncogenes such as c-myc are responsible for cell proliferation and tumor progression [Bonomi 
et al., 2013]. In A549 lung cancer cells, exposure to MLAuNP caused a significant 1.56-fold 
decrease in c-myc levels (0.04 ± 0.00 RBD vs control: 0.07 ± 0.00 RBD, p < 0.05) (Figure 8). 
This led to the assessment of p53, a tumor suppressor gene which was significantly increased by 
1.17-fold (0.13 ± 0.00 RBD vs control: 0.11 ± 0.01, p < 0.05) (Figure 8). MLAuNP treated A549 
cells further demonstrated a significant increase in pro-apoptotic proteins such as Bax (1.34-
fold, 0.12 ± 0.00 RBD vs control: 0.09 ± 0.00 RBD, p < 0.001) and Smac/DIABLO levels 
(1.52-fold, 0.10 ± 0.00 RBD vs control: 0.07 ± 0.00 RBD, p < 0.0001) (Figure 8). During 
apoptosis PARP-1 is cleaved and exposure to MLAuNP caused the cleavage and activation of 
PARP-1.  A 1.30-fold increase in PARP-1 24 kDa fragment was seen (0.23 ± 0.00 RBD vs 
control: 0.17 ± 0.00 RBD, p < 0.0001) (Figure 8). Interestingly, SRp30a, an alternate splicing 
factor, was increased by 1.13-fold in A549 treated cells (0.05 ± 0.01 RBD vs control: 0.04 ± 
0.00 RBD, p = 0.428) (Figure 8). In addition, anti-apoptotic Bcl-2 protein was decreased (1.30-
fold) by MLAuNP compared to the control (0.11 ± 0.01 RBD vs 0.14 ± 0.01 RBD, p < 0.05) 
(Figure 8). Furthermore Hsp70 was also significantly reduced (1.30-fold, 0.57 ± 0.00 RBD vs 







Quantification of mRNA  
The mRNA levels of c-myc, p53, skp2 and Fbw7α in A549 cells was determined using qPCR 
relative to the control (Figure 9). The c-myc mRNA levels were decreased 1.44 ± 0.05-fold (p < 
0.001) in MLAuNP treatment (Figure 9). A 1.77 ± 0.12-fold (p < 0.05) increase in p53 mRNA 
levels was observed in MLAuNP treated cells. Skp2 levels decreased by 7.33-fold ± 0.01 (p < 
0.0001) and Fbw7α decreased by 2.82-fold ± 0.04 (p < 0.0001) in MLAuNP treatment (Figure 9).  
 
 
Figure 9 The mRNA levels of c-myc, p53, skp2 and Fbw7α in A549 cells 
mRNA levels were differential expressed in A549 cells after exposure to MLAuNP for 24h (***p 
< 0.0001, **p < 0.001, *p < 0.05).  
 
Alternate splicing of caspase-9 







Figure 10 The effect of MLAuNP on alternate splicing of caspase-9 in A549 cells  
Caspase-9a (A) and caspase-9b (B) levels were determined by densitometric analysis of qPCR 
product (C) (**p < 0.001, *p < 0.05). MLAuNP activated alternate splicing with a significant 
increase in caspase-9a splice variant. 
 
MLAuNP activated alternate splicing of capase-9 in A549 cancer cells resulting in both a 
significant 1.68-fold (**p < 0.001) increase in pro-apoptotic caspase-9a and a 1.67-fold (*p < 
0.05) decrease in caspase-9b levels (Figure 10). Analysis of the alternate splice variants of 
caspase-9 showed that MLAuNP changed the caspase-9a/caspase-9b ratio from 0.63 ± 0.03 to 
1.76 ± 0.08 in the cancer cells.   
 
Discussion 
Lung cancer is characterised by uncontrolled cell growth, loss of normal functionality and 
evasion of apoptosis [Ho et al., 2010]. Current anticancer therapies possess adverse effects and 
are becoming drug resistant and hence new and more effective agents are actively being 
investigated. An effective treatment regime for lung cancer will not only increase survival rates 
but also improve quality of life [Montazeri et al., 2001]. Nanoparticles have huge potential in 
the treatment of various cancers [Lim et al., 2011; Selim and Hendi, 2012]. MLAuNP was 
synthesised using MO crude aqueous leaf extract in an environmentally friendly synthesis 
(Figure 2 - Figure 6). The leaf components possess reducing potential which aided in the green 
synthesis of the AuNP’s [Anand et al., 2014]. There are many phytochemicals present in the 
leaf extract which includes phenolic acids and flavonoids such as gallic acid, itaconic acid and 





chemical composition of Moringa oleifera aqueous leaf extract by GC-MS analysis showed that 
it mainly contained hydrocarbons and phenolic compounds (Figure 1). Pyran-4-one, 2-
Furancarboxaldehyde, Docosane, Tetracosane, Pentacosane, Heptacosane and Octacosane were 
identified as major chemical constituents. They play a role in the reduction of the metal ions to 
form the gold nanoparticles. Gallic acid, a bioactive compound present in the leaf extract can act 
as a reducing and stabilising agent [Li et al., 2015]. MLAuNP and CAuNP induced cytotoxicity and 
decreased cell viability in A549 lung and SNO oesophageal cancer cells in a dose-dependent 
manner (Figure 7), whilst no cytotoxicity was observed in normal healthy PBMCs (Figure 7). 
MLAuNP as compared to CAuNP, induced greater cytotoxicity and increased antiproliferative 
effects in both cancerous A549 and SNO cells, reducing A549 and SNO cell viability to 19% 
and 31% respectively. However CAuNP only reduced A549 and SNO cell viability to 53% and 
44% respectively. This shows the selective targeting of AuNP’s to cancerous cells, with 
increased selectivity by the MLAuNP. In addition, MLAuNP was not cytotoxic to normal healthy 
PBMC’s and the increased PBMC’s cell viability may be due to the bioactive compounds 
present in the aqueous crude leaf extract such as glutamine [Ndubuaku et al., 2013; Roth et al., 
2002]. Due to minimal toxicity observed in PBMCs, we investigated the mechanism of cell 
death induced by MLAuNP in A549 and SNO cells. 
 
The c-myc oncoprotein, a basic helix-loop-helix leucine-zipper transcription factor, regulates 
genes controlling cell growth and proliferation [An et al., 2008]. Lung cancer cells have 
increased c-myc expression. The ubiquitin-proteasome pathway is responsible for the 
proteolysis of c-myc involving the F-box protein and ubiquitin ligase components, whilst c-myc 
mRNA and protein stability contributes to its role in carcinogenesis [Kim et al., 2014]. 
Posttranslational regulation of c-myc is via Skp2 and Fbw7α [Chen et al., 2013], that are 
different regulation subunits of the SCF-type E3 ligase (Skp1/Cullin/F-box protein complexes) 
responsible for proteasomal degradation. The c-myc/Skp2/Fbw7α pathway is linked to tumor 
progression and is therefore a potential target for anticancer agents [Chen et al., 2013]. c-Myc 
increases Skp2 expression which also acts as a co-factor increasing c-myc’s transcriptional 
activity [Kim et al., 2014]. Glycogen synthase kinase 3 (Gsk3) mediates Fbw7α degradation of 
c-myc. Gsk3 phosphorylates threonine 58 residue on c-myc which serves as a recognition site 
for Fbw7α. MLAuNP significantly decreased both c-myc mRNA and protein expression in A549 
cells (Figure 8 and Figure 9). Also Skp2 levels were significantly decreased (Figure 9). This 
influences c-myc’s transcriptional function hence the inhibition of its proliferative effect. In 
addition, Skp2 causes the degradation of p27 (cyclin dependent kinase inhibitor) thus allowing 





and inhibition of cell proliferation [Dai et al., 2006; Kim et al., 2014]. Drug resistant cancers 
often have decreased Fbw7 expression which acts as a tumor suppressor [Chen et al., 2013; Dai 
et al., 2006]. MLAuNP significantly decreased Fbw7α mRNA levels (Figure 9). The anticancer 
effect of Wogonin in A549 cells was due to decreased c-myc, Skp2 and Fbw7α levels [Chen et 
al., 2013]. The induction of apoptosis occurred independently of Fbw7α. Similarly, MLAuNP 
decreased c-myc, Skp2 and Fbw7α levels suggesting a possible role in drug-resistant cancers.  
 
The p53 tumor suppressor gene functions by regulating cell growth, proliferation and apoptosis. 
In cancer cells, p53 function is often dysregulated thereby allowing abnormal cells to continue 
to proliferate. MLAuNP treatment caused a significant increase in p53 mRNA and protein 
expression (Figure 8 and Figure 9). A consequence of increased p53 expression resulted in 
increased expression of Bax, a pro-apoptotic protein and a simultaneous decrease in the anti-
apoptotic Bcl-2 protein (Figure 8).  Furthermore the induction of apoptosis through the 
activation of Bax causes it to bind to voltage-dependent anion channel (VDAC) and influences 
its activity [Hengartner, 2000]. The VDAC protein forms a subunit of the mitochondrial 
permeability transition pore (MPTP). The depolarization of the mitochondrial membrane by 
MLAuNP opens the MPTP resulting in cytochrome c (cyt c) release from the mitochondria into 
the cytoplasm, together with ATP. A consequence is that Apaf-1 cleaves procaspase-9 resulting 
in activation of caspase-9 (Table 2).  
 
The regulation of gene and protein expression is a determinant of cell fate. The serine/arginine-
rich proteins (SR proteins) are required for alternate splicing [Manley and Krainer, 2010]. The 
alternate pre-mRNA processing of caspase-9 gene produces two splice variants, the pro-
apoptotic caspase-9a and the anti-apoptotic caspase-9b [Massiello and Chalfant, 2006; Shultz et 
al., 2011; Shultz et al., 2010]. The inclusion of exon 3, 4, 5, 6 cassette results in caspase-9a 
splice variant and the induction of apoptosis. Caspase-9b (exon exclusion) competes with 
caspase-9a for binding to the apoptosome. SRp30a is an important splicing factor in the 
alternative splicing of caspase-9 [Massiello and Chalfant, 2006] and MLAuNP increased SRp30a 
protein expression (Figure 8) thus activating alternate splicing of pre-mRNA in A549 cells. 
There was a significant increase in caspase-9a with a concomitant decrease in caspase-9b 
mRNA levels in A549 cells (Figure 10). MLAuNP increased the caspase-9a/caspase-9b ratio from 
0.63 to 1.76. Our findings are consistent with those of Massiello and Chalfant. (2006), where 
ceramide treated A549 cells resulted in alternate splicing of caspase-9 with increased capase-9a 
and decreased caspase-9b splice variants [Massiello and Chalfant, 2006]. The ratio of caspase-





trans-acting factor (regulating splicing factor) involved in the pre-mRNA processing and its 
downregulation favoured caspase-9b at the expense of caspase-9a [Massiello and Chalfant, 
2006]. The increased expression of caspase-9a splice variant by MLAuNP resulted in an increase 
in caspase-9 activity. Increased caspase-9 caused activation of the executioner caspases-3/7 
leading to apoptosis (Table 2). These observations strongly suggest that MLAuNP preferentially 
targets the mitochondria and induces apoptosis via the intrinsic pathway. Furthermore, MLAuNP 
in SNO cells displayed a greater increase in caspase activity as compared to CAuNP (Table 2). 
The results show that MLAuNP can be used as an antiproliferative agent. 
 
In addition, during the execution of apoptosis, poly (ADP-ribose) polymerase 1 (PARP-1), a 
nuclear enzyme, is cleaved into an 89 kDa C-terminal catalytic fragment and a 24 kDa N-
terminal DNA-binding domain fragment [D'Amours et al., 2001]. MLAuNP actively induced 
PARP-1 cleavage in A549 cells as evidenced by the significant increase in the 24 kDa fragment 
(Figure 8) confirming the execution of apoptosis. Further, PS externalization [Schlegel and 
Williamson, 2001] was also significantly increased by  MLAuNP  (Table 2).  
 
Inhibitor of apoptosis protein (IAP), contain baculoviral IAP repeat (BIR) domains, is an 
intracellular protein that inhibits caspase activity [Hengartner, 2000; Wang, 2001]. 
Smac/DIABLO which is concurrently released with cyt c from the mitochondria, binds to the 
BIR domain of IAP thus antagonising its action and ensures the execution of apoptosis [Fischer 
and Schulze-Osthoff, 2005]. MLAuNP significantly increased Smac/DIABLO protein levels 
(Figure 8). Our data clearly shows that MLAuNP induces and promotes apoptosis in A549 lung 
cancer cells. Hsp70, a chaperone molecule, inhibits key effectors in apoptosis [Garrido et al., 
2006] and are highly expressed in cancer cells. Hsp70 inhibits apoptosome formation as it binds 
to Apaf-1 and prevents the recruitment of procaspase-9, thus inhibiting apoptosis and enabling 
the cancer cells to continue proliferation. In our study, Hsp70 expression was significantly 
reduced by MLAuNP (Figure 8), thus ensuring the effective execution of apoptosis and the 
inability of the cancer cells to continue proliferation.  
 
Selim and Hendi, (2012) showed the induction of apoptosis by chemically synthesised AuNP’s 
in an MCF-7 (breast cancer) cell line [Selim and Hendi, 2012]. AuNP’s significantly increased 
p53, Bax, caspase-3 and caspase-9 and decreased Bcl-2 expression. Another study showed that 
AuNP’s decreased GSH levels, increased mitochondrial depolarisation and ultimately led to cell 
death in HL7702 cells [Gao et al., 2011]. Chemically synthesised AuNP’s also caused A549 cell 





synthesis of AuNP’s using a plant extract from Podophyllum hexandrum showed 
antiproliferative properties in human cervical carcinoma cells (HeLa cells) [Jeyaraj et al., 2014]. 
The green synthesis of AuNP’s by MO leaves shows promise as an anticancer agent by inducing 
increased apoptosis in lung cancer cells. The development of nanoparticles has shown potential 
in therapies which ultimately improve survival rates [Leong and Ng, 2014]. Synthesised 
AuNP’s inhibited ovarian cancer cell growth in a size and concentration dependent manner 
[Arvizo et al., 2013]. It also inhibited MAPK-signalling with a reversal of the epithelial-
mesenchymal transition in the cancer cells displaying antiproliferative and anti-metastatic 
properties. The physico-chemical properties of NP’s depends on the size, shape, charge, 
hydrophobicity as well as functional groups which facilitates their interaction with biological 
systems however the mechanism of action is still to be fully elucidated [Davis et al., 2008; Tay 
et al., 2014]. 
 
MLAuNP was successfully produced in a one-pot green synthesis by MO leaves. The synthesised 
MLAuNP was not cytotoxic to normal healthy PBMCs but was cytotoxic and induced apoptosis, 
via the intrinsic pathway, in cancerous A549 lung cells. MLAuNP targeted oncogenes, tumor 
suppressor genes and was able to activate alternate splicing of caspase-9 to effectively execute 
the apoptotic cascade in lung cancer cells. In addition, MLAuNP caused a dose-dependent 
decrease in SNO cancer cell viability and activated caspase activity, showing that MLAuNP has an 
affinity affect cancer cells. Further, MLAuNP showed greater reduction in cell viability in A549 
cells as compared to Trisodium citrate gold nanoparticles (CAuNP) (chemically synthesised gold 
nanoparticles); MLAuNP as compared to CAuNP also induced higher caspase activity in cancerous 
SNO cells - showing it specifically targets cancer cells.     
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DISCUSSION, CONCLUSION AND RECOMMENDATIONS 
 
South Africa has a diverse range of plants and trees which are readily available for traditional 
medicinal use [1]. More than 3000 species are used for herbal remedies which have shown 
potential in treatment of various ailments including cancer. A growing interest into the local 
biodiversity of our plant kingdom and their medicinal potential has led to the expansion of 
indigenous knowledge and medical use. Although modern medicine has advanced 
tremendously, the rate of disease progression especially in developing countries are also 
advancing with uncontrollable side-effects. Traditional medicinal plants and trees may provide 
positive outcomes in chronic diseases with minimal side-effects. Of the many traditional 
medicinal trees available, MO is readily used by many South Africans. 
 
In SA, cancer mortality (especially lung and oesophageal cancer) is increasing at a rapid rate. 
The high mortality rates are due to late stage detection which increases the aggressive nature of 
cancer cells [2, 3]. Therefore, early detection and diagnosis will allow for treatment with 
positive outcomes. Unfortunately, the cost associated with early detection and subsequent 
treatments are relatively high, in addition to the many side-effects, which necessitates for 
complementary and alternative medicines (CAM). CAM can be beneficial to cancer patients as 
it is not only cost-effective but also induces cancerous cell death. This study investigated the 
antiproliferative and apoptosis inducing effects of MOE and its synthesised AuNP’s in human 
cancer cells in vitro. 
 
First, it was shown that MOE possessed antiproliferative effects in A549 lung cancer cells [4]. 
MOE increased ROS production which compromised cellular membranes via lipid peroxidation 
[5]. It specifically targeted Nrf2 and significantly reduced its levels with a subsequent decrease 
in GSH levels. MOE induced significant oxidative stress accompanied by DNA damage and 
p53 upregulation. This resulted in induction of programmed cell death via the mitochondria 
(intrinsic pathway of apoptosis). In addition, MOE increased Smac/DIABLO expression and 
cleavage of PARP-1 to ensure lung cancer cell death. Similarly, in SNO oesophageal cancer 
cells, MOE significantly increased oxidative stress by increasing lipid peroxidation and 
significantly decreasing antioxidant response, viz., Nrf2, GSH and catalase levels. This led to 
oxidative DNA damage and execution of the apoptotic cascade via p53 activation. In addition, 
apoptotic markers such as PS externalisation, Smac/DIABLO and PARP-1 cleavage were 





MOE is composed of various phytochemicals which is vital for the antiproliferative effect seen 
in cancer cells. Amongst the several bioactive compounds such as gallic acid, rhamnose, 
glucosinolates and isothiocyanates [6], niazimicin has been identified to have potent anticancer 
properties [7]. It has been shown that niazimicin had anticancer properties by inhibiting Epstein-
Barr-virus-early antigen activation in Raji cells induced by a tumour promoter [7]. Further in 
vivo tests showed that it had anticancer effects in two-stage carcinogenesis in mouse skin. 
Niazimicin delayed tumour promotion by 50% and papilloma formation by 80% after 10 weeks 
in mice. MOE exerted anticancer activity in B16 F10 melanoma tumours in mice [8]. MOE 
inhibited cell proliferation and tumour growth in comparison to the control. The anticancer 
property was attributed to phytochemical constituents including niazimicin. It has also been 
shown that MOE decreased NFkB signalling pathway and inhibited cell proliferation in Panc-1 
cells [9]. MOE caused cells to accumulate in the G1 phase of the cell cycle. It also worked 
synergistically with cisplatin to induce cytotoxicity in pancreatic cancer cells. MOE also 
displayed cytoprotective effects against lead induced hepatotoxicity in wistar rats [10]. Lead 
treatment caused increased hepatocyte damage as alkaline phosphatase, amino transferase and 
alanine amino transferase levels were elevated with a decrease in catalase activity. Following 
exposure to MOE, the damage caused by lead was reversed.   
 
Existing chemotherapies are non-specific [11] and selective targeting by anticancer agents is 
ideal. MOE was then used in an environmentally friendly synthesis of gold nanoparticles 
(MLAuNP). The GC-MS analysis showed that MOE contained many bioactive compounds such 
as Pyran-4-one, 2-Furancarboxaldehyde, Docosane, Tetracosane, Pentacosane, Heptacosane and 
Octacosane which facilitated the synthesis of MLAuNP’s. A one pot green synthesis technique 
[12] was used to synthesise the novel MLAuNP successfully. As compared to chemically 
synthesised CAuNP, MLAuNP induced greater cytotoxicity in both A549 and SNO cells. The 
MLAuNP was more effective in selective targeting, albeit in a unicellular system, and inducing 
apoptosis of lung and oesophageal cancer cells. Interestingly, MLAuNP was not cytotoxic to 
normal healthy PBMCs but modulated oncogenes, tumour suppressor genes and alternate 
splicing of caspase-9 to effectively induce apoptosis in A549 lung cancer cells. In cancers, there 
is dysregulation of oncogenes (e.g. c-myc) and tumour suppressor genes (e.g. p53) which 
promotes tumour progression. MLAuNP significantly decreased c-myc levels with a simultaneous 
increase in p53 levels which signalled for apoptosis via the mitochondria. Alternate splicing is 
regulated by SR proteins such as SRp30a. Irregular alternate splicing in cancer cells leads to 
chemotherapy resistance as the isoforms expressed results in differing functionality. Cancer 





resistance. The alternate processing of caspase-9 gene produces two splice variants, the pro-
apoptotic caspase-9a and the anti-apoptotic caspase-9b [13-15]. Caspase-9 alternate splicing 
has shown that the caspase-9b splice variant (anti-apoptotic) enhances chemotherapy resistance 
[16]. MLAuNP increased SRp30a which favoured caspase-9a splice variant and subsequently 
increased caspase-9 activity to effectively execute apoptosis in A549 lung cancer cells. 
Dysregulated alternate splicing facilitates cell growth, angiogenesis, tumour development, 
cancer metabolism, evasion of apoptosis and chemotherapy resistance [17]. Therefore, targeting 
alternate splicing in cancer cells can be effective in therapy. It has been shown that there is 
dysregulated alternate splicing in renal cancer cells when compared to their paired control [18]. 
The caspase9a/caspase-9b ratio was affected with higher expression of caspase-9b which was 
similar to survivin splice variant expression leading to inhibition of apoptosis. Also alternate 
splicing of GLI1, an oncogenic transcription factor, was dysregulated resulting in increased 
expression of anti-apoptotic molecules and resistance to cell death.   
 
Cancer cells increase their resistance by inducing an antioxidant response, elevating GSH levels 
to reduce ROS [17]. Synthesis of GSH is dependent on the availability and functionality of 
cysteine and cystine transporter system (xCT and CD98hc). CD44 has multiple functions and 
plays a role in inter cell and matrix interactions as well as migration and invasion. Alternate 
splicing of CD44 produces CD44 v8-10 which increases GSH levels by interacting with cystine 
transporter xCT. This results in reduced oxidative damage by reducing ROS levels. This was 
evident in CD44v-positive 4T1 mouse breast cancer cells. It increased xCT activity and GSH 
levels. These mice then developed lung metastatic lesions demonstrating its role in metastasis. 
The splicing factor ESRP1 is responsible for the alternate splicing of CD44. The decreased 
expression of the splicing factor prevented lung metastasis. Regulation of alternate splicing 
especially in cancer cells is imperative as cellular fate is thereby determined.  
 
MO seedpods were used in the synthesis of AuNP’s [19]. The seedpod extract caused the 
reduction of chloroauric acid resulting in AuNP’s formation. The phytochemical screening of 
the extract also showed it contained flavonoids, alkaloids, terpenes, saponins and phenols. The 
extract possessed antibacterial effects against B. subtilis, S. aureus, E. coli and K. pneumonia. 
The synthesised AuNP’s showed hepatoprotective properties in HepG2 cells. B-chronic 
lymphocytic leukaemia is resistant to apoptosis as a result of increased VEGF secretion from 
cancerous cells [20]. VEGF causes neovascularisation and cell survival therefore anti-VEGF 
antibody can be utilised to induce apoptosis in cancer cells. Anti-VEGF antibody were 





synthesised conjugated AuNP’s decreased anti-apoptotic molecules and caused a significant 
cleavage of PARP-1 showing potential of AuNP’s as an anticancer agent.   
 
A study conducted on AuNP’s effects on Vero, MRC-5 and NIH3T3 cells showed that AuNP’s 
specifically induced apoptosis only in Vero cells [21]. However, in MRC-5 cells, AuNP’s 
caused DNA damage and induced a cellular repair response. AuNP’s induced autophagy in 
NIH3T3 cells as cell growth was slowed. It has been shown that stable AuNP’s can be 
synthesised using MOE [22]. However biocompatibility and cytotoxicity of the synthesised 
AuNP’s required further investigations. 
 
It was shown that MOE, possess antiproliferative properties in vitro by inducing apoptosis (the 
intrinsic apoptotic pathway) in both lung and oesophageal cancer cell lines via increased 
oxidative stress, DNA fragmentation and pro-apoptotic molecules. Interestingly, both MOE and 
MLAuNP were only cytotoxic to cancer cells and not on normal healthy cells (PBMCs). This 
shows the selective targeting of MOE and MLAuNP to cancerous cells. In addition, exposure to 
MOE had a greater increase in PBMCs cell viability as compared to MLAuNP. This can be 
attributed to MOE’s constituents i.e. glutamine which plays a role in nutrition and cellular 
metabolism [23, 24]. Glutamine is required by lymphocytes for cellular proliferation and 
activation. Also, exposure to glutamine stimulated DNA, RNA and protein synthesis in 
hepatocytes [24], demonstrating its role in cell proliferation.  Taken together the results from 
our study indicate the potential use of MOE as a complementary and alternative medicine for 
lung and oesophageal cancer. Further, MLAuNP also induced apoptosis in A549 lung cancer cells 
via classical splicing and up-regulation of the pro-apoptotic caspase-9a variant. In addition, 
MLAuNP induced caspase activity for the induction of apoptosis in SNO oesophageal cancer 
cells. 
 
In conclusion, both MOE and MLAuNP have potential against cancer as they displayed the potent 
apoptotic inducing properties. Fractionation and purification studies of the crude extract are 
further recommended for future studies. In addition, an assessment of the safety and efficacy of 
MOE and MLAuNP in an in vivo and cancer model will be beneficial. Gallic acid was identified 
as a bioactive compound present in the leaf extract which is a potential compound for future 
tests. Cancer cell resistance to therapy can be due to membrane transport proteins such as the 
ABCC family and p-glycoprotein which causes an efflux of anticancer drugs preventing their 
therapeutic potential. By targeting these membrane transport proteins, there will be an 





apoptosis. In addition, the cell cycle, cyclin-CDK complex and IAP’s are also possible target 
points which are further recommended for investigation. 
  
The main limitation of this study is the use of a unicellular/monolayer cell culture system. In 
order to show selective cancer cell targeting by MOE and its synthesised MLAuNP’s, an 
assessment in an in vivo rodent model (with induced lung cancer) will be beneficial. Further, an 
evaluation in a healthy model will assess the safety, bio-distribution and efficacy of MOE and 
MLAuNP. Furthermore, by inducing lung cancer in the rodents (in vivo testing), we can assess the 
antiproliferative effect and selective cancer cell targeting in a multicellular system.  
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Moringa oleifera leaves were collected from the KwaZulu-Natal region (Durban, South 




































Chapter 2 - The antiproliferative effect of Moringa oleifera crude aqueous leaf extract on 
cancerous human alveolar epithelial cells - Supplementary material  
 
DNA damage 
DNA damage was determined using the Comet assay. Following treatment of cells (20,000 
cells/well) in a 6-well plate, supernatants were removed and cells were trypsinized. Three slides 
per sample were prepared as the first layer of 1% low melting point agarose (LMPA, 37°C), 
second layer of 25μl of cells (20,000) from the samples with 175μl of 0.5% LMPA (37°C) and 
third layer of 0.5% LMPA (37°C) covered the slides. After solidification, the slides were then 
submerged in cold lysing solution [2.5M NaCl, 100mM EDTA, 1% Triton X-100, 10mM Tris 
(pH 10), 10% DMSO] and incubated (4°C, 1h). Following incubation the slides were placed in 
electrophoresis buffer [300mM NaOH, 1mM Na2EDTA (pH 13)] for 20min and thereafter 
subjected to electrophoresis (25V, 35min, RT) using Bio-Rad compact power supply. The slides 
were then washed 3 times with neutralisation buffer [0.4M Tris (pH 7.4)] for 5min each. The 
slides were stained overnight (4°C) with 40μl ethidium bromide (EtBr) and viewed with a 
fluorescent microscope (Olympus IXSI inverted microscope with 510-560nm excitation and 
590nm emission filters). Images of 50 cells and comets were captured per treatment and the 
comet tail lengths were measured using Soft imaging system (Life Science - ©Olympus Soft 






















Figure 1 DNA damage was assessed using the Comet assay and comet tails length were 









Western Blots were performed to determine the expression of Nrf2, p53, Smac/DIABLO and 
PARP-1. Briefly, total protein was isolated using Cytobuster™ reagent supplemented with 
protease inhibitor (Roche, cat. no. 05892791001) and phosphatase inhibitor (Roche, cat. no. 
04906837001). The bicinchoninic acid assay (Sigma, Germany) was used to quantify the 
protein and was standardised to 2.042mg/ml. The samples were prepared in Laemmli buffer, 
boiled (100°C, 5min) and electrophoresed (150V, 1h) in 7.5% sodium dodecyl sulfate 
polyacrylamide gels using a Bio-Rad compact power supply. The separated proteins were 
electro-transferred to nitrocellulose membrane using the Trans-Blot® Turbo Transfer system 
(Bio-Rad) (20V, 45min). The membranes were blocked (1h) using 3% BSA in Tris-buffered 
saline containing 0.5% Tween20 (TTBS - NaCl, KCL, Tris, Tween 20, dH2O, pH 7.4). 
Thereafter, the membranes were immune-probed with primary antibody [Nrf2 (ab89443), p53 
(ab26), PARP-1 (ab110915), 1:1,000; Smac/DIABLO (ab68352), 1:200] at 4°C overnight. The 
membranes were then washed 4x with TTBS (10min each) and incubated with the secondary 
antibody (ab97046; 1:2,000) at RT for 1h. The membranes were finally washed 4x with TTBS 
(10min each). To correct for loading error and to normalise the expression of the proteins, β-
actin was assessed (ab8226; 1:5,000). Horse radish peroxidase (HRP) chemiluminescence 
detector and enhancer solution was used for the antigen-antibody complex and the signal was 
detected with the Alliance 2.7 image documentation system (UViTech). The expression of the 
proteins were analysed with UViBand Advanced Image Analysis software v12.14 (UViTech). 















Figure 2 Western blot was used to determine the expression of proteins in relative band density 
(RBD) of Nrf2 (A), p53 (B), Smac/DIABLO (C), PARP-89 kDa (D) and 24 kDa (E) fragment 
in A549 cells after treatment with MOE. The expression of Nrf2 in MOE treated cells were 
significantly decreased compared to the untreated control [Figure 2A (0.069 ± 0.007 RBD vs 
0.129 ± 0.022 RBD, p < 0.05). There was a significant increase in p53 expression [Figure 2B 
(0.567 ± 0.002 RBD vs control: 0.558 ± 0.002 RBD, p < 0.05)] and Smac/DIABLO expression 
[Figure 2C (1.509 ± 0.055 RBD vs control: 1.425 ± 0.007 RBD, p = 0.162)]. MOE caused 
PARP cleavage into an 89 kDa and 24 kDa fragment with a significant decrease in PARP 89 
kDa fragment expression compared to the control [Figure 2D (0.234 ± 0.005 RBD vs 0.297 ± 
0.005 RBD, p < 0.0001)]. The PARP 24 kDa fragment was significantly increased [Figure 2E 







Data analysis for western blot  
 
1) Nrf2 
Table 1 The normalisation of the expression of Nrf2 in the control 
Treatments  RBD 1 RBD 2 RBD 3 
Control 23118944 31714632 24647880 
β-actin 205612604 205612604 205612604 
 
0.112 0.154 0.120 
 
Table 2 The normalisation of the expression of Nrf2 in the MOE treatment  
Treatments  RBD 1 RBD 2 RBD 3 
MOE 16219257 17313580 13970162 
β-actin 230473898 230473898 230473898 
 
0.070 0.075 0.061 
 
Table 3 The expression of Nrf2 in A549 cells treated with MOE for 24h  





Control 0.112 0.154 0.120 0.129 0.022 1 
MOE 0.070 0.075 0.061 0.069 0.007 1.89 
   
 
2) p53 
Table 4 The normalisation of p53 expression in the control 
Treatments RBD 1 RBD 2 RBD 3 
Control 8609 8566 8636 
β-actin 15394 15394 15394 











Table 5 The normalisation of p53 expression in the MOE treatment  
Treatments RBD 1 RBD 2 RBD 3 
MOE 9661 9606 9648 
β-actin 16986 16986 16986 
 
0.569 0.566 0.568 
 
Table 6 The expression of p53 in A549 cells treated with MOE for 24h  





Control 0.559 0.556 0.561 0.558 0.002 1 




Table 7 The normalisation of the expression of Smac/DIABLO in the control 
Treatments RBD 1 RBD 2 RBD 3 
Control 22059 21905 21969 
β-actin 15428 15428 15428 
 
1.430 1.420 1.424 
 
Table 8 The normalisation of the expression of Smac/DIABLO in the MOE treatment  
Treatments RBD 1 RBD 2 RBD 3 
MOE 22551 23743 22266 
β-actin 15335 15335 15335 
 
1.471 1.548 1.509 
 
Table 9 Smac/DIABLO expression in A549 cells treated with MOE for 24h  
Treatments RBD 1 RBD 2 RBD 3 Mean RBD SD Fold change 
Control 1.430 1.420 1.424 1.425 0.007 1 









4)  *PARP 89 kDa  
Table 10 The normalisation of PARP 89 kDa expression in the control 
Treatments RBD 1 RBD 2 RBD 3 
Control 6521 6369 6299 
β-actin 21520 21520 21520 
 
0.303 0.296 0.293 
 
Table 11 The normalisation of PARP 89 kDa expression in the MOE treatment  
Treatments RBD 1 RBD 2 RBD 3 
MOE 4495 4644 4662 
β-actin 19623 19623 19623 
 
0.229 0.237 0.238 
 
Table 12 The expression of PARP 89 kDa in A549 cells treated with MOE for 24h  
Treatments RBD 1 RBD 2 RBD 3 
Mean 
RBD SD Fold change 
Control 0.303 0.296 0.293 0.297 0.005 1 
MOE 0.229 0.237 0.238 0.234 0.005 1.27 
 
 
* PARP 24 kDa  
Table 13 The normalisation of the expression of PARP 24 kDa in the control 
Treatments RBD 1 RBD 2 RBD 3 
Control 6559 5977 5941 
β-actin 21520 21520 21520 
 
0.305 0.278 0.276 
 
Table 14 The normalisation of the expression of PARP 24 kDa in the MOE treatment  
Treatments RBD 1 RBD 2 RBD 3 
MOE 8452 8291 7913 
β-actin 19623 19623 19623 
 







Table 15 PARP 24 kDa expression in A549 cells treated with MOE for 24h 
Treatments RBD 1 RBD 2 RBD 3 Mean RBD SD 
Fold 
change 
Control 0.305 0.278 0.276 0.286 0.016 1 





























Phytochemical analysis of Moringa oleifera aqueous leaf extract 
 
 
Figure 1 Chemical composition of MOE by GC-MS analysis 
 
MOE showed eleven peaks in the GC-MS chromatogram. The compounds were separated 
according to their retention time on fused silica capillary column. The total ion chromatogram 
(TIC) indicates the presence of various organic compounds with significant abundant peaks at 
retention time 7.55, 8.75, 10.87, 12.22, 14.26, 19.36, 20.24, 21.21, 22.34, 22.72 and 25.44 min 
having molecular ions (m/z) of 144.0, 126.0, 142.0, 58.0, 60.0, 310.0, 338.0, 352.0, 279.0, 366.0 
and 380.0 respectively. These compounds mainly comprised of hydrocarbons and phenolic 
compounds. Pyran-4-one (7.55), 2-Furancarboxaldehyde (8.75), Docosane (19.36), Tetracosane 
(21.21), Pentacosane (22.34), Heptacosane (23.72) identified as major chemical constituents 








1.  Al-Owaisi, M., Al-Hadiwi, N., Khan, S.A. GC-MS analysis, determination of total 
phenolics, flavonoid content and free radical scavenging activities of various crude 






































SNO cell viability assay   
SNO cell viability was determined using the 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-
tetrazolium bromide (MTT) assay. Cells (20,000cells/well) were seeded into a 96-well 
microtitre plate. The cells were incubated with varying MOE dilutions (0.1-10mg/ml) in six 
replicates (300µl/well) and incubated (37ºC, 5% CO2) for 48 and 72h. Control cells were 
incubated with CCM only. A CCM/MTT salt solution (5mg/ml) was added (120µl/well) and the 
plate was incubated (37ºC, 4h). Thereafter, supernatants were removed; dimethyl sulphoxide 
(DMSO) 100µl/well was added and incubated (1h). The optical density of the formazan product 
was measured (570/690nm) using a spectrophotometer (Bio Tek μQuant). The results were 
expressed as percentage cell viability relative to the control. This experiment was repeated on 
two separate occasions before the concentration of half the maximum inhibition (IC50) of MOE 
for SNO cells were determined. 
 
 







Figure 2 SNO cell viability treated with MOE for 72h   
 
A dose-dependent decline in SNO cell viability was seen after exposure to MOE for 48 and 72h. 



























Protein quantification and standardisation 
The bicinchoninic acid assay (BCA) (Sigma, Germany) was used to quantify the isolated 
protein. Bovine serum albumin (BSA) standards (0-1mg/ml) were prepared in dH2O. 25µl of 
each BSA standards, samples and 202µl BCA working solution (BCA, CuSO4) was added per 
well and incubated (37°C, 30min). The optical density was measured on a spectrophotometer 
(Bio Tek μQuant) at 562nm. The data was analysed and expressed in mg/ml from the linear 
equation generated from the standard curve. The concentration of protein for each sample was 
determined and subsequently standardised. 
 
1) The antiproliferative effect of Moringa oleifera crude aqueous leaf extract on cancerous 
human alveolar epithelial cells 
 
Figure 1 Standard curve using known concentrations of bovine serum albumin for determining 
sample protein concentration using bicinchoninic acid assay  
 
Table 1: Standardisation of protein samples (A549 cells exposed to MOE) using the standard 













Control 1.377 2.042 2.042 100 100 





2) The antiproliferative effect of Moringa oleifera crude aqueous leaf extract on human 
oesophageal cancer cells 
 
Figure 2 Standard curve using known concentrations of bovine serum albumin for determining 
sample protein concentration using bicinchoninic acid assay  
 
Table 2: Standardisation of protein samples (SNO cells exposed to MOE) using the standard 













Control 2.306 1.555 1 64.3 100 














3) Moringa oleifera gold nanoparticles modulate oncogenes, tumor suppressor genes and 
caspase-9 splice variants in A549 cells. 
 
Figure 3 Standard curve using known concentrations of bovine serum albumin for determining 
sample protein concentration using bicinchoninic acid assay  
 
Table 3: Standardisation of protein samples (A549 exposed to MLAuNP) using the standard 













Control 2.312 2.986 1.066 71.4 200 
MOE 1.892 2.437 1.066 87.5 200 
 
 
 
 
